<!DOCTYPE html>
<html class="">

<head>
   <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
   <title>Pulmonary embolism - Approach | BMJ Best Practice</title>
   <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
   <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
   <meta name="description"
      content="Pulmonary embolism (PE) is a life-threatening condition resulting from dislodged thrombi occluding the pulmonary vasculature; right heart failure and cardiac arrest may ensue if not aggressively treated. Symptoms include chest pain, dyspnoea, and a sense of apprehension. Haemoptysis and syncope a...">

   <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
   <link rel="stylesheet" type="text/css" media="screen" href="../css/css-to-sass.css">
<link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
   <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
   <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">

</head>

<body class="gpw">
   <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc"
      class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 cc-invisible"
      style="display: none;">
      <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to
         tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To
         learn more about how we use cookies, please see our
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link"
            href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
      <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0"
            class="cc-btn cc-dismiss">OK!</a></div>
      <!--googleon: all-->
   </div>
   <!-- Google Tag Manager (noscript) -->
   <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0"
         style="display:none;visibility:hidden"></iframe></noscript>
   <!-- End Google Tag Manager (noscript) -->
   <!-- /* if user in China */ -->
   <header id="header" role="banner">
      <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#sr-content">Skip to
         main content</a>
      <div class="bg-info text-white">
      </div>
      <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
         <div class="container">
            <a href="https://bestpractice.bmj.com/" class="mobLogo"><span class="remove"><abbr>BMJ</abbr> Best
                  Practice</span></a>
            <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse"
               data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
            </button>
            <div id="navbarNav" class="collapse navbar-collapse">
               <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                  <li id="globalNav-access" class="nav-item" role="presentation">
                     <span class="nav-link">
                        Access provided by:
                        BMJ Group (Online access from BMA House)
                     </span>
                  </li>
                  <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#"
                        id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown"
                        aria-haspopup="true" aria-expanded="false">
                        Help <span class="states">
                           <span class="material-icons"></span>
                           <span class="material-icons"></span>
                        </span>
                     </a>
                     <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right"
                        aria-labelledby="navbarDropdownMenuLink02">
                        <span class="material-icons"></span>
                        <ul role="menu">
                           <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/"
                                 target="_blank">Getting started</a></li>
                           <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/"
                                 target="_blank">FAQs</a></li>
                           <li class="dropdown-item"><a
                                 href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/"
                                 target="_blank">About CME/CPD</a></li>
                           <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/"
                                 target="_blank">Contact us</a></li>
                        </ul>
                     </div>
                  </li>
                  <li id="globalNav-register" class="nav-item">
                     <a href="https://bestpractice.bmj.com/registration" class="nav-link">Create account</a>
                  </li>
                  <li id="globalNav-login" class="nav-item">
                     <a href="https://bestpractice.bmj.com/login" class="nav-link">Log in</a>
                  </li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/recent-updates"><span
                           class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/specialties"><span
                           class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/calculators"><span
                           class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/patient-leaflets"><span
                           class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/procedural-videos"><span
                           class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/evidence"><span
                           class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                  <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link"
                        href="https://bestpractice.bmj.com/drugs"><span
                           class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
               </ul>
            </div>
         </div>
      </nav>
      <div id="mainSearch" class="container">
         <div class="row">
            <div class="col-lg-7">
               <div class="logo-img"><a href="https://bestpractice.bmj.com/"><span class="remove"><abbr
                           title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
            </div>
            <div class="col-lg-5">
               <style type="text/css">
                  #searchBoxWrap .tt-open:before {
                     content: "Recently viewed topics:";
                  }

                  #searchBoxWrap .tt-label-override:before,
                  #searchBoxWrap .tt-suggested:before {
                     content: "Suggested topics:" !important;
                  }
               </style>
               <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search"
                  novalidate="novalidate">
                  <div class="input-group">
                     <div id="searchBoxWrap">
                        <label for="q" class="sr-only">Search</label>
                        <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                           <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value=""
                              class="tt-input" autocomplete="off" spellcheck="false" dir="auto"
                              style="position: relative; vertical-align: top;">
                           <pre aria-hidden="true"
                              style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                           <div class="tt-menu"
                              style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                              <div class="tt-dataset tt-dataset-0"></div>
                           </div>
                        </span>
                        <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                     </div>
                  </div>
               </form>
               <script>
                  /*<![CDATA[*/

                  // These are required in completion, see BP-232
                  var searchDefaultLanguageCode = "en-gb";
                  var regionName = "GB and ROW";
                  var regionAvailableLanguagesCodes = [{
                     "id": "1",
                     "code": "en-gb",
                     "displayName": "English"
                  }, {
                     "id": "3",
                     "code": "pt-br",
                     "displayName": "Portugu\u00EAs"
                  }, {
                     "id": "5",
                     "code": "es-es",
                     "displayName": "Espa\u00F1ol"
                  }, {
                     "id": "7",
                     "code": "ru-ru",
                     "displayName": "\u0420\u0443\u0441\u0441\u043A\u0438\u0439"
                  }];
                  var availableLanguages = [];

                  for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                     availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                  }
                  /*]]>*/
               </script>
            </div>
         </div>
      </div>
      <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
         <div class="container">
            <div id="mainNavbarNav">
               <ul class="navbar-nav" role="menubar">
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/recent-updates"><span
                           class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/specialties"><span
                           class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/calculators"><span
                           class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/patient-leaflets"><span
                           class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/procedural-videos"><span
                           class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/evidence"><span
                           class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                  <li class="nav-item main" role="menuitem"><a class="nav-link"
                        href="https://bestpractice.bmj.com/drugs"><span
                           class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
               </ul>
            </div>
         </div>
      </nav>
   </header>
   <main id="tmp" class="container tmp tmp-basic main-container" role="main">
      <script type="text/javascript">
         /*<![CDATA[*/
         var topicId = 116;
         var langCode = "en-gb";
         /*]]>*/
      </script>
      <div id="topicNav" class="container">
         <div class="lang">
            <ul role="menu">
               <li><a href="https://bestpractice.bmj.com/topics/en-gb/116" class="active">English</a></li>
               <li><a href="https://bestpractice.bmj.com/topics/pt-br/116">Português</a></li>
               <li><a href="https://bestpractice.bmj.com/topics/es-es/116">Español</a></li>
               <li><a href="https://bestpractice.bmj.com/topics/ru-ru/116">Русский</a></li>
            </ul>
         </div>
         <div id="topicMenuTopBg" style="height: 110px;"></div>
         <div id="topicMenuTopWrap" style="height: 110px;">
            <div id="topicMenuTop" style="height: 110px;">
               <h1>Pulmonary embolism</h1>
               <div class="pdf-links-nav">
                  <div class="pdf">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                     </a>
                  </div>
               </div>
               <div id="mobileMenu" class="mUp">
                  <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                  </a>
               </div>
               <ul id="menuLinks" role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-0"
                        aria-owns="menu-0">Overview <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-1"
                        aria-owns="menu-1">Theory <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-2"
                        aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-3"
                        aria-owns="menu-3">Management <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-4"
                        aria-owns="menu-4">Follow up <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-5"
                        aria-owns="menu-5">Resources <span class="material-icons"></span><span
                           class="material-icons"></span></a></li>
               </ul>
            </div>
         </div>
         <div id="topicMenuBottomWrap" style="height: 176px;">
            <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 176px;">
               <ul id="menus" role="menubar">
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Overview</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-0">
                        <li><a href="116_overview_summary.html" id="Summary">Summary</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Theory</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-1">
                        <li><a href="116_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                        <li><a href="116_theory_aetiology.html" id="Aetiology">Aetiology</a></li>
                        <li><a href="116_theory_case_history.html" id="Case history">Case history</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Diagnosis</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-2">
                        <li><a href="116_diagnosis_recommendations.html" id="Approach">Recommendations</a></li>
                        <li><a href="116_diagnosis_history-exam.html" id="History and exam">History and exam</a></li>
                        <li><a href="116_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                        <li><a href="116_diagnosis_differentials.html" id="Differentials">Differentials</a></li>
                        <li><a href="116_diagnosis_criteria.html" id="Criteria">Criteria</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Management</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-3">
                        <li><a href="116_management_recommendations.html" id="Approach"
                              class="active">Recommendations</a></li>
                        <li><a href="116_management_treatment_algorithm.html" id="Treatment algorithm">Treatment
                              algorithm</a></li>
                        <li><a href="116_management_emerging.html" id="Emerging">Emerging</a></li>
                        <li><a href="116_management_prevention.html" id="Prevention">Prevention</a></li>
                        <li><a href="116_management_patient_discussions.html" id="Patient discussions">Patient
                              discussions</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Follow
                           up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                     <ul role="menu" id="menu-4">
                        <li><a href="116_follow_up_monitoring.html" id="Monitoring">Monitoring</a></li>
                        <li><a href="116_follow_up_complications.html" id="Complications">Complications</a></li>
                        <li><a href="116_follow_up_prognosis.html" id="Prognosis">Prognosis</a></li>
                     </ul>
                  </li>
                  <li>
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#"
                        class="parent"><span>Resources</span><span class="material-icons"></span><span
                           class="material-icons"></span></a>
                     <ul role="menu" id="menu-5">
                        <li><a href="116_resources_guidelines.html" id="Guidelines">Guidelines</a></li>
                        <li><a href="116_resources_images_videos.html" id="Images and videos">Images and videos</a></li>
                        <li><a href="116_resources_references.html" id="References">References</a></li>
                        <li><a href="116_resources_patient_leaflets.html" id="Patient leaflets">Patient leaflets</a>
                        </li>
                        <li><a href="116_resources_evidence.html" id="Evidence">Evidence</a></li>
                     </ul>
                  </li>
                  <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf"
                        target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View
                           PDF</span></a></li>
               </ul>
            </nav>
         </div>
      </div>
      <h2 id="sr-content">Recommendations</h2>
      <div class="invest poce_contents">
         <div class="card p-3 mb-4">
            <div class="card-block poce_urgent">
               <section>
                  <h3>Urgent</h3>
                  <ul class="w-75">
                     <li><p class="w-75"><strong>Assess for signs of shock or hypotension (ABCDE approach), which can indicate a
                           high-risk (massive/central) PE.</strong>
                        <ul>
                           <li><p class="w-75"><strong>Seek senior support and escalate to critical care</strong> if suspected.
                              [ESC][ACP][NICE]</p></li>
                           <li><p class="w-75"><strong>A high-risk PE</strong> is defined as a systolic blood pressure <strong>(SBP)
                                 &lt;90 mmHg or a SBP drop by &ge;40 mmHg for &gt;15 minutes</strong>, if not caused by
                              a new-onset arrhythmia, hypovolaemia, or sepsis. [ESC]</p></li>
                           <li><p class="w-75"><strong>Signs of shock</strong> include altered cognition, cool extremities, mottled or
                              ashen skin, slow capillary refill, and oliguria.</p></li>
                        </ul>
                     </p></li>
                     <li><p class="w-75"><strong>If the patient is in peri-arrest/cardiac arrest and PE is suspected </strong>it is
                        common practice<strong> to give thrombolysis immediately </strong>without waiting for results of
                        investigations (based on discussion between senior clinicians).</p></li>
                     <li><p class="w-75"><strong>Give intravenous fluids if SBP &lt;90 mmHg or there are other signs of shock.
                           [ESC]</strong>
                        <ul>
                           <li><p class="w-75">Give either normal saline or Hartmann&rsquo;s; start with a <strong>500 mL fluid
                                 challenge</strong>.</p></li>
                           <li><p class="w-75"><strong>Monitor for signs of heart failure.</strong> [ESC] The leading cause of death in
                              patients with high-risk PE is acute right ventricular (RV)failure with resulting
                              hypotension.</p></li>
                        </ul>
                     </p></li>
                     <li><p class="w-75"><strong>Ensure early respiratory support.</strong>
                        <ul>
                           <li><p class="w-75"><strong>Titrate oxygen to 94% to 98% </strong>(or 88% to 92% in patients at risk of
                              hypercapnic respiratory failure).</p></li>
                           <li><p class="w-75">Use mechanical ventilation if necessary. Beware that this can worsen hypotension so
                              monitor blood pressure closely. [ESC] [BTS02]</p></li>
                        </ul>
                     </p></li>
                     <li><p class="w-75"><strong>Arrange emergency primary reperfusion for any patient with shock or hypotension
                           (high-risk PE). [ESC] [ACP]</strong>
                        <ul>
                           <li><p class="w-75">Systemic thrombolysis is the standard treatment of choice.</p></li>
                           <li><p class="w-75"><strong>Do not allow supportive therapy to delay thrombolysis</strong>, which may quickly
                              restore haemodynamic stability.</p></li>
                           <li><p class="w-75">Use vasoactive drugs if SBP remains &lt;90 mmHg after thrombolysis and adequate fluid
                              resuscitation.</p></li>
                        </ul>
                     </p></li>
                     <li><p class="w-75"><strong>Give anticoagulation early if indicated. [NICE][ESC][ACP]</strong>
                        <ul>
                           <li><p class="w-75"><strong>Check the patient has no contraindications</strong> to anticoagulation</p></li>
                           <li><p class="w-75"><strong>You do not need to wait for the results of investigations</strong> to give
                              anticoagulation if PE is highly suspected.</p></li>
                           <li><p class="w-75"><strong>Be aware of special cases </strong>such as pregnancy, renal impairment, and
                              active cancer as these groups will need a specific type/dose of anticoagulant.</p></li>
                        </ul>
                     </p></li>
                  </ul>
               </section>
            </div>
         </div>

         <div id="odf" class="mb-4">
            <h3 class="mb-1">Key Recommendations</h3>

            <div class="card mb-4 p-4">
               <div class="card-block">
                  <div class="row">
                     <div class="col-md-8">
                        <img src="../images/RecommendationsManagementV2.png" class="w-100" style="max-width: 700px; " />
                     </div>
                     <div class="col-md-4">
                        <ol style="list-style-type: lower-alpha;">
                           <li><p class="w-75">‘Highly suspected’ PE includes all patients with either a positive D-dimer or Wells score
                              >4, or haemodynamically stable patients with evidence of RV dysfunction on
                              echocardiography.</p></li>
                           <li><p class="w-75">Cardiac biomarkers include high sensitivity troponin (I or T), BNP, or NT-proBNP.</p></li>
                           <li><p class="w-75">Use clinical exclusion criteria in combination with PESI/sPESI when making a decision
                              regarding discharge.</p></li>
                        </ol>
                     </div>
                  </div>
                  <div class="row">
                     <div class="col-md-12">

                     </div>
                  </div>

               </div>
            </div>


            <div class="row">
               <div class="col-md-9">
                  Click below to see a full list of recommendations
               </div>
               <div class="col-md-3 text-right">
                  <h3><a href="https://bestpractice.bmj.com/topics/en-gb/116/investigations#">
                        <span class="hidden-sm-down">
                           <span class="msg">VIEW ALL</span>
                           <span class="material-icons" role="button"><span></span><span></span></span>
                        </span>
                     </a>
                  </h3>
               </div>
            </div>
            <div class="card">
               <div class="card-block">
                  <div class="container">
                     <div id="1" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse" data-target="#collapseTest-1">
                           <h3 id="odf-2342423-scsfdsf">Initial supportive treatment for haemodynamically unstable
                              (high-risk) PE [ESC][BTSO2]</h3>
                        </div>
                     </div>
                     <div id="collapseTest-1" class="row rowDetails p-3 collapse">
                        <ul class="w-75">
                           <li><p class="w-75"><strong>Ensure early respiratory support.</strong> Titrate oxygen to 94% to 98% (or 88%
                              to 92% for patients at risk of hypercapnic failure).<ul>
                                 <li><p class="w-75">Use mechanical ventilation if necessary but monitor blood pressure closely.</p></li>
                              </ul>
                           </p></li>

                           <li><p class="w-75"><strong>If the patient is in peri-arrest or cardiac arrest and PE is suspected it is
                                 common practice to give thrombolysis </strong>without waiting for results of
                              investigations.<ul>
                                 <li><p class="w-75">This decision will be made by senior clinicians.</p></li>
                              </ul>
                           </p></li>

                           <li><p class="w-75"><strong>If SBP &lt;90 mmHg or there are other signs of shock, use intravenous
                                 fluids</strong>; start with a 500 mL fluid challenge.<ul>
                                 <li><p class="w-75">Some studies indicate that aggressive volume expansion is of no benefit and may
                                    even worsen RV function so monitor for signs of heart failure. [ESC]</p></li>
                              </ul>
                           </p></li>

                        </ul>
                        <p class="w-75"><strong>Do not allow supportive therapy to delay thrombolysis in high-risk PE</strong> (as
                           long as there are no contraindications) as this may quickly restore haemodynamic stability.
                        </p>
                     </div>
                     <div id="2" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse" data-target="#collapseTest-2">
                           <h3 id="odf-2342423-234">Further acute management of haemodynamically unstable (high-risk)
                              patients [ESC][ACP]</h3>
                        </div>
                     </div>
                     <div id="collapseTest-2" class="row rowDetails p-3 collapse">
                        <ul>
                           <li><p class="w-75"><strong>Seek senior support when managing any patient who is haemodynamically unstable
                                 and has had PE either</strong>
                              <ul>
                                 <li><p class="w-75">confirmed on CTPA or</p></li>
                                 <li><p class="w-75">highly suspected (unequivocal signs of RV dysfunction on echocardiography) .</p></li>
                              </ul>
                           </p></li>
                           <li><p class="w-75">Ensure all such patients receive both anticoagulation and thrombolysis (unless
                              contraindicated) as follows:
                              <ul>
                                 <li><p class="w-75">Anticoagulation with unfractionated heparin (UFH) initially, provided there are no
                                    contraindications. This should be started prior to primary reperfusion.
                                    <ul>
                                       <li><p class="w-75">Continue anticoagulation with UFH for several hours after the end of
                                          thrombolysis before switching to a low molecular weight heparin (LMWH; e.g.,
                                          dalteparin, enoxaparin), fondaparinux, apixaban, or rivaroxaban.
                                          [ESC]<br />AND</p></li>
                                    </ul>
                                 </p></li>
                                 <li><p class="w-75">Thrombolysis (if there are no contraindications).
                                    <ul>
                                       <li><p class="w-75">Select an accelerated thrombolysis regimen, administered over 2 hours.</p></li>
                                       <li><p class="w-75">In practice, almost any contraindication should be considered only relative
                                          in haemodynamically unstable patients with PE because the high mortality risk
                                          is likely to outweigh any bleeding risk.</p></li>
                                    </ul>
                                 </p></li>
                                 <li><p class="w-75"><strong>If the patient continues to deteriorate despite thrombolysis (or if
                                       thrombolysis is absolutely contraindicated after discussion with haematology),
                                       consider surgical embolectomy or percutaneous catheter-directed therapy
                                       (depending on local expertise and availability).</strong></p></li>
                              </ul>
                           </p></li>
                           <li><p class="w-75"><strong>Give a vasoactive drug if SBP remains &lt;90 mmHg </strong>despite adequate
                              intravenous fluids and thrombolysis.[ESC]</p></li>
                        </ul>
                     </div>
                     <div id="3" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse" data-target="#collapseTest-3">
                           <h3 id="odf-245234-scsfdsf">Acute phase anticoagulation in haemodynamically stable patients
                           </h3>
                        </div>
                     </div>
                     <div id="collapseTest-3" class="row rowDetails p-3 collapse">
                        <p class="w-75"><strong>Give anticoagulation to all of the following groups unless
                              contraindicated:[NICE][ESC]</strong></p>
                        <ul>
                           <li><p class="w-75">Patients with <strong>confirmed PE</strong> either on CTPA or echocardiography.</p></li>
                           <li><p class="w-75">Patients who present with<strong> suspected PE and have either a positive D-dimer or a
                                 Wells score &gt;4</strong>. If PE is subsequently excluded, anticoagulation should be
                              discontinued</p></li>
                        </ul>

                        <p class="w-75"><strong>Decide on the type of anticoagulant based on a patient&rsquo;s comorbidities and
                              contraindications </strong>as well as taking into account <strong>local
                              guidelines</strong>.</p>
                        <ul>
                           <li><p class="w-75"><strong>LMWH, rivaroxaban, apixaban, or fondaparinux </strong>are all options. Dabigatran
                              and edoxaban are not recommended as the initial anticoagulant in these patients because
                              they require lead-in therapy with a parenteral anticoagulant first.</p></li>
                           <li><p class="w-75"><strong>Be aware of special patient groups such as pregnancy, renal impairment, and
                                 active cancer</strong> as these groups will need a specific type/dose of anticoagulant.
                           </p></li>
                           <li><p class="w-75"><strong>Consult a haematologist if a patient has a contraindication to
                                 anticoagulation.</strong> Many of these patients, even those with apparent absolute
                              contraindications, may still be able to have a different or altered dose of an
                              anticoagulant.</p></li>
                        </ul>
                     </div>
                     <div id="4" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse" data-target="#collapseTest-4">
                           <h3 id="odf-2342423-2313131">Risk stratification</h3>
                        </div>
                     </div>
                     <div id="collapseTest-4" class="row rowDetails p-3 collapse">
                        <p class="w-75"><strong>Risk stratify haemodynamically stable patients using the PESI or sPESI score
                           </strong>(the full Pulmonary Embolism Severity Index score, or its simplified sPESI
                           version).[BTS] [ESC]</p>

                        <ul>
                           <li><p class="w-75"><strong>Monitor any intermediate-risk patient (PESI &ge;III or sPESI &ge;1) closely for
                                 signs of cardiopulmonary deterioration.</strong> Consider primary reperfusion (rescue
                              thrombolysis) if a patient in this group shows signs of deterioration or their SBP falls
                              to &lt;90 mmHg.</p></li>
                           <li><p class="w-75"><strong>Consider low-risk patients (PESI I or II, or sPESI 0) for early
                                 discharge.</strong>
                              <ul>
                                 <li><p class="w-75">PE does not need to be confirmed on CTPA prior to discharge but it should be
                                    performed within 24 hours (if available) [BTS]</p></li>
                              </ul>
                           </p></li>
                           <li><p class="w-75"><strong>Assessment of RV size/function on CTPA or echocardiography is not obligatory
                              </strong>for the identification of low-risk patients for outpatient management [BTS].
                              </strong>
                              <ul>
                                 <li><p class="w-75">Consider measuring cardiac biomarkers (high sensitivity troponin, BNP or NT-proBNP)
                                    in patients who have evidence of RV dysfunction on CTPA/echo if performed during
                                    diagnostic work-up and who are suitable for outpatient management. If these are
                                    normal they can be considered for discharge. If they are elevated they should be
                                    admitted for observation. [BTS]</p></li>
                              </ul>
                           </p></li>
                        </ul>

                        <p class="w-75"><strong>Do not use risk stratification scores for haemodynamically unstable
                              patients.</strong></p>
                        <ul>
                           <li><p class="w-75">Treat any such patient as high-risk.</p></li>
                        </ul>
                        <p class="w-75"><strong>Do not use PESI/sPESI scoring in pregnant women.</strong></p>
                     </div>
                     <div id="5" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse" data-target="#collapseTest-5">
                           <h3 id="odf-2342423-234">Ongoing anticoagulation post-PE</h3>
                        </div>
                     </div>
                     <div id="collapseTest-5" class="row rowDetails p-3 collapse">
                        <p class="w-75"><strong>The standard duration of anticoagulation should cover at least 3
                              months</strong>.[ESC][NICE]</p>
                        <ul>
                           <li><p class="w-75">Longer-term, or sometimes indefinite, anticoagulation may be needed for secondary
                              prevention after weighing the individual patient&rsquo;s risk of recurrence versus
                              bleeding risk.</p></li>
                        </ul>

                        <p class="w-75"><strong>Select either a direct-acting oral anticoagulant (DOAC) or warfarin (a vitamin K
                              antagonist) according to the patient&rsquo;s characteristics and preferences</strong></p>
                        <ul>
                           <li><p class="w-75">If a DOAC is chosen:[ESC][NICEAC]<ul>
                                 <li><p class="w-75">Rivaroxaban or apixaban can be continued if started during the acute phase.</p></li>
                                 <li><p class="w-75">Dabigatran or edoxaban require lead-in therapy with a parenteral anticoagulant for
                                    at least 5 days before starting treatment with them. The parenteral anticoagulant
                                    should be stopped before starting dabigatran or edoxaban.</p></li>
                              </ul>
                           </p></li>
                           <li><p class="w-75">If warfarin is chosen, it should be overlapped with a parenteral anticoagulant for at
                              least 5 days or until the INR is &ge;2 for at least 24 hours (whichever is the
                              longer).[NICE]</p></li>
                        </ul>

                        <p class="w-75">Some patients may continue on LMWH or fondaparinux rather than switching to an oral
                           anticoagulant (e.g., patients with active cancer, pregnant women).</p>
                        <p class="w-75"><strong>Anticoagulation can usually be stopped after 3 months following a provoked PE. [NICE]
                              [ESC]</strong></p>
                        <ul>
                           <li><p class="w-75">A provoked PE is one associated with a reversible or transient risk factor that was
                              present in the prior 3 months (e.g. surgery, trauma, immobility, pregnancy, use of oral
                              contraception or hormone replacement therapy)</p></li>
                        </ul>
                        <p class="w-75"><strong>Anticoagulation is typically continued for &gt;3 months after an unprovoked PE.
                              [NICE] [ESC]</strong></p>
                     </div>


                  </div>
               </div>
            </div>
         </div>

         <div id="fullRecs">
            <h2>Full recommendations</h2>
            <div class="row">

               <div class="col-md-9">

                  <p class="w-75">Click below to see a full list of recommendations</p>
               </div>
               <div class="col-md-3 text-right">
                  <h3><a href="https://bestpractice.bmj.com/topics/en-gb/116/investigations#">
                        <span class="hidden-sm-down">
                           <span class="msg">VIEW ALL</span>
                           <span class="material-icons" role="button"><span></span><span></span></span>
                        </span>
                     </a>
                  </h3>
               </div>
            </div>
            <div class="card">
               <div class="card-block">
                  <div class="container">
                     <div id="6" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse" data-target="#collapseTest-6">
                           <h3>Treatment goals</h3>
                        </div>
                     </div>
                     <div id="collapseTest-6" class="row rowDetails p-3 collapse">
                        <p class="w-75"><strong>The main treatment goals are to:</strong></p>
                        <ul>
                           <li><p class="w-75">Provide <strong>supportive treatment </strong>and give<strong> early reperfusion therapy
                              </strong>to any patient who is<strong> haemodynamically unstable </strong>(usually
                              <strong>thrombolysis</strong>,but in rare cases may be surgical embolectomy/percutaneous
                              catheter-directed therapy).</p></li>
                           <li><p class="w-75"><strong>Ensure anticoagulation is given early</strong> to any patient with either
                              confirmed or highly clinically suspected PE.</p></li>
                           <li><p class="w-75"><strong>Risk stratify </strong>haemodynamically stable patients and plan ongoing
                              management based on<strong> PESI/sPESI score.</strong></p></li>
                           <li><p class="w-75"><strong>Identify underlying risk factors</strong> that have provoked the PE</p></li>
                        </ul>
                     </div>
                     <div id="7" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse" data-target="#collapseTest-7">
                           <h3>Supportive therapy in haemodynamically unstable (high-risk) patients</h3>
                        </div>
                     </div>
                     <div id="collapseTest-7" class="row rowDetails p-3 collapse">
                        <p class="w-75"><strong>Patients with suspected or confirmed PE who present with shock or hypotension are at
                              high risk of in-hospital death</strong>, particularly in the<strong> first few
                              hours</strong> after presentation. [ESC]</p>
                        <ul>
                           <li><p class="w-75"><strong>Seek immediate senior input and escalate to the critical care
                                 team.</strong></p></li>
                        </ul>

                        <div id="tip_pitfall" class="card card-inverse mb-4">
                           <div class="card-block">
                              
                              <h3 class="card-title">Do not allow supportive therapy to delay thrombolysis in these
                                 patients (as long as there are no contraindications) - thrombolysis may quickly restore
                                 haemodynamic stability.</h3>
                              <ul>
                                 <li><p class="w-75">It is common practice to give thrombolysis as first-line treatment for any patient
                                    who is in peri-arrest /cardiac arrest based on clinical suspicion of PE without
                                    waiting for results from investigations.</p></li>
                                 <li><p class="w-75">In these situations the decision to thrombolyse would be based on discussion
                                    between senior clinicians.</p></li>
                              </ul>
                           </div>
                        </div>

                        <div class="evidence-accordion">
                           <div class="option">
                              <input type="checkbox" id="toggle1" class="toggle" />
                              <label class="title" for="toggle1">
                                 <span class="material-icons"><span></span></span>
                                 <span class="title">Evidence: Patients with high-risk PE are at significant risk of
                                    death</span>
                              </label>
                              <div class="content">
                                 <ul>
                                    <li><p class="w-75"><strong>The 30-day mortality rate of patients with haemodynamically unstable
                                          (high-risk) PE ranges from 16 to 25% and that of patients with cardiac arrest
                                          due to PE ranges from 52 to 65%</strong>. [TANABE][KASPER]
                                       <ul>
                                          <li><p class="w-75">Most deaths in patients presenting with shock occur within the first hour
                                             after presentation so rapid therapeutic action is essential to save lives.
                                             [HENRY]</p></li>
                                          <li><p class="w-75">The International Cooperative Pulmonary Embolism Registry (ICOPER) showed
                                             90-day mortality rates of 58.3% in patients with high-risk (massive) PE.
                                             [GOLD]</p></li>
                                       </ul>
                                    </p></li>
                                    <li><p class="w-75"><strong>The vast majority of patients with PE present without cardiogenic shock
                                          and with normal or only mildly reduced blood pressure. </strong>
                                       <ul>
                                          <li><p class="w-75">These patients have an overall 30-day mortality rate of about 6% and are
                                             considered as non-high-risk patients. [BOVA]</p></li>
                                          <li><p class="w-75">In these patients, right heart strain on echocardiography or evidence of
                                             myocardial injury has been shown to be associated with an increased risk of
                                             clinical deterioration and/or short-term death. Other factors, such as an
                                             elevated troponin (indicating cardiac ischemia), altered mental status, and
                                             the presence of comorbidities have also been correlated with early clinical
                                             deterioration and higher risk of short-term death. [TRINQUART] [BECATTINI]
                                          </p></li>
                                          <li><p class="w-75">In a meta-analysis of six studies involving 2874 haemodynamically stable
                                             patients with PE and evidence of myocardial injury and/or RV dysfunction,
                                             follow up at 30 days showed PE-related death in 90 patients, haemodynamic
                                             collapse in 122 patients and nonfatal symptomatic recurrent PE in 18
                                             patients. [DAVID]</p></li>
                                          <li><p class="w-75">An analysis of 298 consecutive patients with low-risk PE (haemodynamically
                                             stable, no rise in cardiac markers and no evidence of RV dysfunction) found
                                             that that around two-thirds suffered no clinical deterioration. [PRUCNAL]
                                          </p></li>
                                       </ul>
                                    </p></li>

                                 </ul>
                              </div>
                           </div>
                        </div>

                        <h3>Oxygen</h3>
                        <p class="w-75"><strong>Give high-concentration oxygen, targeting a saturation of 94% to 98% (or 88% to 92%
                              in any patient at risk of hypercapnic respiratory failure).</strong>[BTS02]</p>
                        <ul>
                           <li><p class="w-75"><strong>Assess oxygen saturation early. </strong>Hypoxaemia is a typical finding in PE.
                              [ESC] The patient may be hypoxic at rest if a high-risk (massive) PE is present or only on
                              exertion with a smaller PE.</p></li>
                           <li><p class="w-75"><strong>Apply mechanical ventilation if required</strong> but use with caution as this
                              may worsen haemodynamic instability in a high-risk (massive) PE. Mechanical ventilation
                              induces positive thoracic pressure which may reduce venous return and worsen right
                              ventricular (RV) failure. [ESC]</p></li>
                        </ul>
                        <h3>Fluid resuscitation</h3>
                        <p class="w-75"><strong>Give intravenous fluids if SBP is &lt;90 mmHg or there are any other signs of
                              shock</strong>. [ESC]</p>
                        <ul>
                           <li><p class="w-75">Give intravenous fluids with <strong>caution </strong>and <strong>start with a 500
                                 mL</strong> fluid challenge. Determine further fluid based on clinical response. [ESC]
                           </p></li>
                           <li><p class="w-75">Use <strong>normal saline (0.9% NaCl) or
                                 Hartmann&rsquo;s/Ringer&rsquo;s</strong><strong>lactate</strong>.[NICEF] Guidelines
                              differ in their recommendations on choice of fluid and clinical practice varies widely so
                              check local protocols.</p></li>
                        </ul>
                        <p class="w-75"><strong>Monitor closely for signs of right heart failure. [ESC]</strong></p>
                        <ul>
                           <li><p class="w-75">The <strong>leading cause of death</strong> in patients with high-risk (massive) PE is
                              <strong>acute right ventricular failure</strong> with resulting hypotension. [ESC]</p></li>
                           <li><p class="w-75">Patients with haemodynamically unstable PE require early intravenous fluid resuscitation
                              but should be monitored for signs of right heart failure.</p></li>
                        </ul>


                        <div class="evidence-accordion">
                           <div class="option">
                              <input type="checkbox" id="toggle2" class="toggle" />
                              <label class="title" for="toggle2">
                                 <span class="material-icons"><span></span></span>
                                 <span class="title">Evidence: Aggressive volume expansion in patients with
                                    haemodynamically unstable PE is of no benefit and may even worsen RV function</span>
                              </label>
                              <div class="content">
                                 <ul>
                                    <li><p class="w-75"><strong>There is only very scarce and conflicting evidence on the balance of
                                          risks versus benefits from fluid resuscitation in patients with PE who are
                                          haemodynamically unstable.</strong>
                                       <ul>
                                          <li><p class="w-75">One prospective study of 13 patients with high-risk haemodynamically
                                             unstable PE suggested that fluid loading (an infusion of 500 mL of dextran
                                             40 over 20 minutes) can improve hemodynamic status. It was shown to
                                             increase right ventricular preload which was associated with an increase in
                                             cardiac index without reducing the right ventricular ejection fraction.
                                             [MERCAT]</p></li>
                                          <li><p class="w-75">In contrast, earlier experimental studies in dogs indicated that
                                             aggressive volume expansion may be of no benefit and may even worsen RV
                                             function. They found that when pulmonary vascular resistance was normal,
                                             volume expansion increased stroke volume (SV) and mean blood pressure
                                             whereas when RV afterload was increased, this volume expansion resulted in
                                             RV failure. [GIRLING][TYBERG].</p></li>
                                       </ul>
                                    </p></li>
                                    <li><p class="w-75"><strong>The 2014 ESC guideline states that evidence to date indicates that
                                          aggressive volume expansion is of no benefit and may even worsen RV
                                          function.</strong> [ESC]</p></li>
                                 </ul>
                              </div>
                           </div>
                        </div>

                     </div>
                     <div id="8" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse" data-target="#collapseTest-8">
                           <h3>Anticoagulation</h3>
                        </div>
                     </div>
                     <div id="collapseTest-8" class="row rowDetails p-3 collapse">
                        <p class="w-75"><strong>Give anticoagulation to all of the following patients (unless
                              contraindicated)</strong>: [ESC][ACP][NICE]</p>
                        <ul>
                           <li><p class="w-75">Those with <strong>PE confirmed </strong>either on CTPA or echocardiography.</p></li>
                           <li><p class="w-75">Those who present with<strong> high clinical probability of PE, based on either a
                                 positive D-dimer or a Wells score &gt;4</strong>. If PE is subsequently excluded,
                              anticoagulation should be discontinued.</p></li>
                        </ul>
                        <p class="w-75"><strong>Anticoagulation is recommended in acute PE to reduce the risk of early death and
                              prevent recurrent symptomatic or fatal VTE. [ESC]</strong></p>

                        <div id="tip_pitfall" class="card card-inverse mb-4">
                           <div class="card-block">
                              
                              <h3 class="card-title">In patients who are haemodynamically unstable, evidence of RV
                                 dysfunction on echocardiography is sufficient to warrant immediate anticoagulation and
                                 thrombolysis.</h3>
                              <ul>
                                 <li><p class="w-75">These patients are normally too unstable to undergo CTPA.</p></li>
                              </ul>
                           </div>
                        </div>
                        <p class="w-75"><strong>The management of subsegmental PE remains controversial </strong></p>
                        <ul>
                        <li><p class="w-75"><strong>Practice varies but <strong>surveillance rather than anticoagulation </strong>is considered the best option for most patients. [ESC]</strong></p></li>
                        </ul>

                        <div class="evidence-accordion">
                           <div class="option">
                              <input type="checkbox" id="toggle3" class="toggle" />
                              <label class="title" for="toggle3">
                                 <span class="material-icons"><span></span></span>
                                 <span class="title">Evidence:  Evidence suggests subsegmental PE may be of little clinical  significance in most cases</span>
                              </label>
                              <div class="content">
                                    <p class="w-75"><strong>The decision over whether to anticoagulate subsegmental PE (SSPE) remains controversial and practice varies widely. Seek specialist advice.</strong></p>
                                    <ul>
                                    <li><p class="w-75">Increasing use of CTPA has increased the number of patients diagnosed with SSPE without any change in mortality rates, suggesting these PEs may not be clinically relevant. [BOONE][BRODER][SOJ]</p></li>
                                    <li><p class="w-75">There may also be overdiagnosis of SSPE. Evidence shows low clinical agreement between radiologists when diagnosing patients with small distal clots as they are subtle and hard to distinguish from artefact. [FRIER]</p></li>
                                    </ul>
                                    <p class="w-75"><strong>European guidelines suggest weighing up clinical probability against the bleeding risk but recommend surveillance rather than anticoagulation for patients who have no proximal DVT and have a low risk of recurrent VTE. [CHEST][ESC] </strong></p>
                                    <ul>
                                    <li><p class="w-75">Evidence on outcomes in patients who are diagnosed with SSPE is scarce and is based on small numbers of patients, making it difficult to formulate evidence-based guidance.</p></li>
                                    <li><p class="w-75">Some studies have shown that anticoagulation may be of no clinical benefit. One meta-analysis examined 750 patients with SSPE, of whom 81% were treated with anticoagulation. Over 90 days there was no difference in mortality or recurrence of PE between those who did and did not receive anticoagulation but 8% of treated patients had an episode of bleeding. [JEFF] In an observational study, 15% (82 patients) of PEs found on CTPA were SSPEs. Around half of these patients were anticoagulated, and 2 developed life-threatening bleeding. No patient had an identified recurrent PE, whether or not they were anticoagulated. [GOY] The risk of recurrence of VTE in patients with SSPE without a concurrent DVT has been found to be insignificant in retrospective studies. [SOJ] [HULL]</p></li>
                                    <li><p class="w-75">On the other hand, a retrospective study of over 3000 patients showed that the rate of recurrence of PE during anticoagulant therapy was the same in patients with SSPE and those with larger PE (ie. segmental or lobar). It also showed that VTE recurrence was higher with SSPE than in those in whom PE was excluded. [KLOK]</p></li>
                                    </ul>
                              </div>
                           </div>
                        </div>

                         <h3>Contraindications to anticoagulation</h3>
                        <p class="w-75"><strong>Consult a haematologist if a patient has a contraindication to anticoagulation.</strong></p>
                        
                        <ul>
                           <li><p class="w-75">Many patients with relative contraindications will still be able to have a different choice or altered dose of anticoagulation but a specialist opinion is needed to weigh up the benefit-risk balance.</p></li>
                           <li><p class="w-75"><strong>Absolute contraindications are rare but include: [HOR]</strong>
                              <ul>
                                 <li><p class="w-75">active bleeding</p></li>
                                 <li><p class="w-75">recent intracranial hemorrhage</p></li>
                                 <li><p class="w-75">recent, planned, or emergent surgery or procedure with high bleeding risk</p></li>
                                 <li><p class="w-75">platelet count &lt;50,000/uL</p></li>
                                 <li><p class="w-75">severe bleeding diathesis.</p></li>
                              </ul>
                           </p></li>
                           <li><p class="w-75"><strong>Relative contraindications include: [HOR]</strong>
                              <ul>
                                 <li><p class="w-75">recurrent but inactive gastrointestinal bleeding</p></li>
                                 <li><p class="w-75">intracranial or spinal tumor</p></li>
                                 <li><p class="w-75">recent, planned, or emergent surgery or procedure with intermediate bleeding risk</p></li>
                                 <li><p class="w-75">major trauma including cardiopulmonary resuscitation</p></li>
                                 <li><p class="w-75">aortic dissection</p></li>
                                 <li><p class="w-75">platelet count &lt;150,000/uL</p></li>
                              </ul>
                           </p></li>
                           <li><p class="w-75"><strong>Remember too that each anticoagulant may have its own specific relative and absolute contraindications</strong> (e.g., heparin is contraindicated in patients with a history of heparin-induced thrombocytopenia), and these should be checked before starting treatment.</p></li>
                        </ul>
                        
                        <div id="tip_pitfall" class="card card-inverse mb-4">
                              <div class="card-block">
                                 
                                 <h3 class="card-title"></h3>
                                 <br/>
                                 <ul>
                                 <li><p class="w-75">Peptic ulcer disease with no history of bleeding or faecal occult blood is not a contraindication to anticoagulation.[HOR]</p></li>
                                 <li><p class="w-75">Anticoagulation is safe in most trauma and neurosurgical patients after the first or second postoperative week and in most stroke patients without haemorrhage. [HOR]</p></li>
                                 <li><p class="w-75">Patients with spinal cord injury without haematomyelia may still be considered for anticoagulation [HOR]</p></li>
                                 </ul>
                              </div>
                           </div>


                           <h3>Types of anticoagulation</h3>
                           <p class="w-75"><strong>Base your choice of anticoagulant on the patient&rsquo;s comorbidities and contraindications as well as taking account of local guidelines.</strong> [NICE]</p>
                           <h2>Acute phase anticoagulation</h2>
                           <h3>Haemodynamically unstable (high-risk) PE</h3>
                           <p class="w-75"><strong>For patients with PE and haemodynamic instability (SBP &lt;90 mmHg or SBP drop of &ge;40 mm Hg for &gt;15 minutes), use UFH.</strong></p>
                           <ul>
                           <li><p class="w-75">UFH has a short half-life, is easy to monitor, and is readily reversed by protamine. [ESC]</p></li>
                           </ul>
                           <p class="w-75"><strong>Start anticoagulation with UFH prior to primary reperfusion with thrombolysis</strong> (or in rare cases surgical embolectomy/catheter-directed therapy).</p>
                           <p class="w-75"><strong>Continue anticoagulation with UFH for several hours after the end of thrombolysis before switching to LMWH, fondaparinux, apixaban, or rivaroxaban</strong>. [ESC] In the UK it is common practice to stop UFH within 24 hours.</p>
                           <ul>
                           <li><p class="w-75"><strong>If switching to LMWH or fondaparinux, the total duration of treatment with UFH and then LMWH or fondaparinux should be at least 5 days. </strong>[NICE][ESC]</p></li>
                           <ul>
                           <li><p class="w-75">If ongoing anticoagulation will be with warfarin, ensure overlap with UFH, LMWH, or fondaparinux for at least 5 days or until the INR is &ge;2 for at least 24 hours (whichever is the longer).[NICE] Seek specialist advice to decide when to start warfarin.</p></li>
                           </ul>
                           </ul>
                           <p class="w-75"><strong>OR</strong></p>
                           <ul>
                           <ul>
                           <li><p class="w-75">If ongoing anticoagulation will be with edoxaban or dabigatran, at least 5 days of lead-in therapy with LMWH or fondaparinux is required first. Stop the LMWH or fondaparinux before starting dabigatran or edoxaban.[BTS]</p></li>
                           </ul>
                           </ul>
                           <ul>
                           <li><p class="w-75"><strong>If switching to rivaroxaban or apixaban, these drugs may be started after stopping UFH without the need for lead-in therapy with LMWH or fondaparinux first</strong>.</p></li>
                           <ul>
                           <li><p class="w-75">Acute-phase treatment consists of an increased dose of the oral anticoagulant over the first 3 weeks (for rivaroxaban), or over the first 7 days (for apixaban).</p></li>
                           </ul>
                           </ul>
                           <p class="w-75"><strong>Seek specialist advice when switching between anticoagulants</strong></p>
                           <ul>
                           <li><p class="w-75">The protocol depends on which anticoagulant you are switching to and from. Haematology input is important.</p></li>
                           </ul>
                           <p class="w-75"><br /><strong>Be aware of special patient groups such as pregnancy, renal impairment, and active cancer</strong> as these groups will need a specific type/dose of anticoagulant. <strong>Seek haematology advice for all patients with hepatic impairment or who are at increased risk of bleeding.</strong></p>
                           <p class="w-75">Browse the best online <a href="https://html-css-js.com/html/" rel="nofollow noopener">HTML tools</a>: editor, tags, cheat sheet, character codes, tag generators, website templates and more.</p>

                           <div class="evidence-accordion">
                                 <div class="option">
                                    <input type="checkbox" id="toggle4" class="toggle" />
                                    <label class="title" for="toggle4">
                                       <span class="material-icons"><span></span></span>
                                       <span class="title">Evidence: There is insufficient evidence to support use of LMWH in haemodynamically unstable (high-risk) PE</span>
                                    </label>
                                    <div class="content">
                                       <p class="w-75"><strong>There is some evidence that LMWH has a similar safety profile to UFH when used prior to thrombolysis.</strong></p>
                                       <ul>
                                       <li><p class="w-75">A prospective, observational multicentre trial showed similar bleeding rates following thrombolysis in patients who had UFH or LMWH. However this evidence remains limited.</p></li>
                                       </ul>
                                       <p class="w-75"><strong>There is not enough evidence to recommend LMWH as a first-line option for patients with PE who are haemodynamically unstable. </strong>[UCAR]</p>
                                    </div>
                                 </div>
                              </div>
      
                              <h3>Haemodynamically stable PE (with the exception of special cases)</h3>
                              <p class="w-75"><strong>Start initial anticoagulation as soon as possible with any one of the following:</strong><strong>LMWH, fondaparinux, apixaban, or rivaroxaban.</strong></p>
                              <ul>
                                 <li><p class="w-75"><strong>If using LMWH or fondaparinux, continue treatment for at least 5 days.</strong>[NICE][ESC]
                                    <ul>
                                    <li><p class="w-75">If ongoing anticoagulation will be with warfarin, start warfarin within 24 hours of diagnosis and ensure overlap with LMWH or fondaparinux for at least 5 days or until the INR is &ge;2 for at least 24 hours (whichever is the longer).[NICE]<br><strong>OR</strong></p></li>
                                    <li><p class="w-75">If ongoing anticoagulation will be with edoxaban or dabigatran, at least 5 days of lead-in therapy with LMWH or fondaparinux is required first. Stop the LMWH or fondaparinux before starting dabigatran or edoxaban.[BTS]</p></li>
                                    </ul>
                                 </p></li>
                                 <li><p class="w-75"><strong>If using rivaroxaban or apixaban, these drugs may be started without the need for lead-in therapy with a parenteral anticoagulant first</strong>.
                                    <ul>
                                       <li><p class="w-75">Acute-phase treatment consists of an increased dose of the oral anticoagulant over the first 3 weeks (for rivaroxaban), or over the first 7 days (for apixaban).</p></li>
                                       <li><p class="w-75">The 2018 British Thoracic Society (BTS) guideline recommends using a single DOAC in patients being considered for outpatient management to minimise potential confusion over dosing and administration.[BTS]</p></li>
                                 </ul>
                                 </p></li>                              
                              </ul>
                              <p class="w-75"><strong>DOACs have non-inferior efficacy and are possibly safer</strong>, <strong>particularly in terms of major bleeding, than the standard regimen of LMWH plus warfarin. </strong>[ESC] [BTS] [ADD CCA link]</p>
                              <ul>
                              <li><p class="w-75">Select a DOAC after discussion with the patient about which regimen would be most suited to them as well as taking into account the risks and benefits of each DOAC.</p></li>
                              </ul>
                              <div id="tip_pitfall" class="card card-inverse mb-4">
                                    <div class="card-block">
                                       
                                       <h3 class="card-title">Never give a DOAC simultaneously with parenteral anticoagulation</h3>
                                       <ul>
                                             <li><p class="w-75">While warfarin is started at the same time as a parenteral anticoagulant and overlapped for at least 5 days or until the INR is &ge;2 for at least 24 hours (whichever is the longer), DOACs should never be overlapped or given at the same time as a parenteral anticoagulant.</p></li>
                                             <li><p class="w-75">Apixaban and rivaroxaban may be started without the need for lead-in therapy with a parenteral anticoagulant first. Either of these DOACs can be used as a single-drug approach; this is why BTS guidelines recommend them as the preferred DOAC options in any patient who might be suitable for early discharge. [BTS]</p></li>
                                             <li><p class="w-75">However, dabigatran and edoxaban require at least 5 days lead-in therapy with a parenteral anticoagulant before starting treatment. The parenteral anticoagulant should be stopped before dabigatran or edoxaban are started.</p></li>
                                             </ul>
                                    </div>
                                 </div>

                                 <div class="evidence-accordion">
                                    <div class="option">
                                       <input type="checkbox" id="toggle5" class="toggle" />
                                       <label class="title" for="toggle5">
                                          <span class="material-icons"><span></span></span>
                                          <span class="title">Evidence: DOACs have emerged as an equally effective and likely  safer option than heparin/warfarin</span>
                                       </label>
                                       <div class="content">
                                             <p class="w-75"><strong>There is now strong evidence that DOACs are non-inferior and have a favourable safety profile for management of PE when compared to either LMWH/warfarin or fondaparinux. [BTS]</strong></p>
                                             <ul>
                                             <li><p class="w-75">Results of the major trials using DOACs in the treatment of VTE indicate that these agents are non-inferior (in terms of efficacy) and possibly safer (particularly in terms of major bleeding) than the standard heparin/warfarin regimen. [WELLS][ESC][GALLUS] [BRENNER] [COCHRANE] [LIB]</p></li>
                                             <li><p class="w-75">A Cochrane review concluded there was [CCA LINK AS ABOVE]</p></li>
                                             <ul>
                                             <li><p class="w-75">no difference between dabigatran and the standard regimen in preventing recurrent VTE (OR 1.02, 95% CI 0.50 to 2.04), recurrent VTE (OR 0.93, 95% CI 0.52 to 1.66) and DVT (OR 0.79, 95% CI 0.29 to 2.13) or in causing major bleeding (OR 0.50, 95% CI 0.15 to 1.68)</p></li>
                                             <li><p class="w-75">no difference between the factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) compared to the standard regimen, in preventing recurrent VTE (OR 0.85, 95% CI 0.15 to 1.68), DVT (OR 0.72, 95% CI 0.39 to 1.32) and all-cause mortality (OR 1.16, 95% CI 0.59 to 1.62) or in causing major bleeding (OR 0.97, 95% CI 0.59 to 1.62).</p></li>
                                             </ul>
                                             <li><p class="w-75">High time in therapeutic range (TTR) values were achieved under warfarin treatment in all trials. On the other hand, the study populations included relatively young patients, very few of whom had cancer.</p></li>
                                             </ul>
                                             <p class="w-75"><strong>Experience with DOACs remains limited but they can be viewed as an alternative to standard treatment.</strong></p>
                                       </div>
                                    </div>
                                 </div>

                                 

                                 <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle6" class="toggle" />
                                          <label class="title" for="toggle6">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence: There is a lack of evidence comparing different DOACs in PE</span>
                                          </label>
                                          <div class="content">
                                             <p class="w-75"><strong>There are no trials that have directly compared different DOACs with each other, so it is difficult to determine which drug should be recommended as a first choice for most patients.</strong></p>
                                             
                                             <ul>
                                                <li><p class="w-75">However, a systematic review, network meta-analysis, and cost effectiveness analysis has indirectly compared DOACs with each other for prevention of stroke in patients with atrial fibrillation. [ META]
                                                   <ul>
                                                      <li><p class="w-75"><strong>The authors concluded that apixaban 5 mg twice daily has the highest expected incremental net benefit</strong>, followed by rivaroxaban 20 mg once daily, edoxaban 60 mg once daily, and dabigatran 150 mg twice daily. It should be emphasised that this analysis was looking at evidence relating to patients with atrial fibrillation on longer-term anticoagulation for stroke prevention. However the different risks/benefits of each anticoagulant can be taken into account when deciding which DOAC to use for a patient with PE. [META]</p></li>
                                                   </ul>
                                                </p></li>
                                                <li><p class="w-75"><strong>Reversal agents exist for dabigatran, apixaban, and rivaroxaban if patients develop serious bleeding or require surgery. There is no licensed reversal agent yet for edoxaban.</strong>
                                                   <ul>
                                                      <li><p class="w-75"><strong>Idarucizumab is licensed to reverse the effect of dabigatran.</strong>
                                                         <ul>                                             
                                                            <li><p class="w-75">Results from an ongoing, uncontrolled, phase III, cohort study (RE‑VERSE AD) of 90 adults taking dabigatran who had either serious bleeding or required urgent surgery, showed that treatment with idarucizumab reversed the anticoagulant effect of dabigatran (median maximum reversal 100%) and normalised dilute thrombin time and ecarin clotting time in 88% to 98% of people.[NEJM]</p></li>
                                                         </ul>
                                                      </p></li>
                                                      <li><p class="w-75"><strong>Andexanet alfa (recombinant coagulation factor Xa) is licensed to reverse the effect of apixaban and rivaroxaban.</strong>
                                                         <ul>
                                                            <li><p class="w-75">Andexanet alfa quickly reverses the anticlotting effects of factor Xa inhibitors, according to an industry-supported study published in the <em>New England Journal of Medicine. </em></p></li>
                                                            <li><p class="w-75">Researchers enrolled 350 adults who presented with acute major bleeding (e.g., intracranial, gastrointestinal) within 18 hours of receiving apixaban or rivaroxaban. Andexanet alfa rapidly reduced anti-factor Xa activity. For example, among patients who'd been receiving apixaban or rivaroxaban, the initial andexanet alfa bolus reduced anti-factor Xa activity by 92%. In addition, at 12 hours after the infusion, 82% of patients were deemed to have good or excellent haemostatic efficacy. [ANDEX]</p></li>
                                                         </ul>
                                                      </p></li>
                                                   <ul>
                                                </p></li>
                                             </ul>
                                          </div>
                                       </div>
                                    </div>

                                     <h3>Haemodynamically stable PE (special patient groups)</h3>
                                     <h3>Pregnancy</h3>
                                    <p class="w-75"><strong>Use a weight-adjusted dose of LMWH in women who are (or may be) pregnant.</strong> [ESC]</p>
                                    <p class="w-75">It does not cross the placenta, and routine monitoring is not generally required. </p>

                                    

                                 <div class="evidence-accordion">
                                    <div class="option">
                                       <input type="checkbox" id="toggle7" class="toggle" />
                                       <label class="title" for="toggle7">
                                          <span class="material-icons"><span></span></span>
                                          <span class="title">Evidence: LMWH is safe and well tolerated in pregnancy</span>
                                       </label>
                                       <div class="content">
                                          <p class="w-75"><strong>Several studies show that heparin is safe to use in pregnancy.</strong></p>
                                          <ul>
                                          <li><p class="w-75">A systematic review and a meta-analysis of the literature was carried out to provide an estimate of the risk of bleeding complications and VTE recurrence in patients with acute VTE during pregnancy treated with either LMWH or UFH. Eighteen studies, giving a total of 981 pregnant patients with acute VTE, were included. It concluded that LMWH and UFH appears to be safe and effective for the treatment of pregnancy-related VTE, but the optimal dosing regimens remain uncertain. [RANCAN]</p></li>
                                          <li><p class="w-75">A case series of 33 women showed that the initial dose of enoxaparin provided satisfactory peak anti-Xa activity. No woman developed thrombocytopaenia, haemorrhagic complication or further thromboembolic episode. Fifteen women had regional anaesthesia for delivery, with a reduced dose of enoxaparin, all without complication. [RODIE]</p></li>
                                          <li><p class="w-75">In a retrospective observational study enoxaparin was administered for treatment of an acute episode in 49 cases and for thromboprophylaxis in 574 cases. Serious maternal haemorrhage occurred in 11 cases during pregnancy (1.8%), one being reasonably related to enoxaparin, and in nine cases at delivery (1.4%), all unrelated to enoxaparin. Maternal thrombocytopenia was reported in 10 cases (1.6%), two being serious but unrelated to enoxaparin. Eight pregnancies ended in stillbirth (1.1%). Among the 693 live births, 17 major congenital abnormalities (2.5%) and 10 serious neonatal haemorrhages (1.4%) were reported. None of the fetal or neonatal adverse events was related to enoxaparin. Eight venous thromboembolic events (1.3%) were reported.The incidence of adverse events reported could be explained by the high risk profile of the study population. Overall, this retrospective study suggests enoxaparin is well tolerated during pregnancy.[BJOG]</p></li>
                                          </ul>
                                       </div>
                                    </div>
                                 </div>

                                 <p class="w-75"><strong>Avoid DOACs and warfarin during pregnancy as they may cross the placenta. [ESC]</strong></p>
                                 <ul>
                                    <li><p class="w-75">Warfarin is associated with a well-defined embryopathy during the first trimester. Administration of warfarin in the third trimester can result in foetal and neonatal haemorrhage, as well as placental abruption. Warfarin may be associated with central nervous system anomalies throughout pregnancy. [ESC]</p></li>
                                    <li><p class="w-75">DOACs are not recommended because there is a lack of evidence of their safety in pregnancy as pregnant women were not included in trials.</p></li>
                                    <li><p class="w-75"><strong>However, warfarin, LMWH, and UFH are compatible with breastfeeding</strong> because they do not accumulate in breast milk and do not lead to anticoagulation in the infant. [ACOG]</p></li>
                                 </ul>

                                  <h3>Active cancer</h3>
                                 <p class="w-75"><strong>Use LMWH in patients with active cancer [NICE] [ACP]</strong></p>
                                 <ul>
                                    <li><p class="w-75"><strong>LMWH is more effective than warfarin in patients with cancer [LINK TO CCA] </strong>
                                       <ul>
                                          <li><p class="w-75">It is also therapeutically reliable in patients for whom oral therapy may be inappropriate (e.g., vomiting), and is easier to adjust/withhold if thrombocytopenia develops or an invasive intervention is needed.[ACP]</p></li>
                                          <li><p class="w-75">Patients with cancer treated with warfarin may be difficult to maintain within the therapeutic range, and experience substantial rates of recurrence. [ACP]</p></li>
                                       </ul>
                                    </p></li>
                                    <li><p class="w-75"><strong>Start the LMWH in the acute phase and continue it for 3-6 months. [NICE]</strong></p></li>
                                 </ul>

                                 <div class="evidence-accordion">
                                    <div class="option">
                                       <input type="checkbox" id="toggle8" class="toggle" />
                                       <label class="title" for="toggle8">
                                          <span class="material-icons"><span></span></span>
                                          <span class="title">Evidence: LMWH vs UFH/warfarin in patients with cancer</span>
                                       </label>
                                       <div class="content">
                                             <p class="w-75"><strong> LMWH administered in the acute phase and continued over the first 3&ndash;6 months is the accepted first-line therapy in patients with cancer (except for high-risk PE). .</strong></p>
                                             <ul>
                                             <li><p class="w-75">A Cochrane review that analysed seven RCTs comparing LMWH with warfarin (after acute-phase heparin) in patients with cancer found a significant reduction in the rate of recurrence of VTE (HR 0.47, 95% CI 0.32 to 0.71) without increased bleeding risk. However, there was no statistically significant reduction in overall mortality (HR 0.96, 95% CI 0.81 to 1.14). [AKL]</p></li>
                                             <li><p class="w-75">An earlier Cochrane review showed a significant reduction in mortality at three months of follow up with LMWH compared with UFH although it showed no statistically significant reduction in VTE recurrence. [MUTI]</p></li>
                                             </ul>
                                             <p class="w-75"><strong>There is some emerging evidence indicating DOACs may be as effective as LMWH.</strong></p>
                                             <ul>
                                             <li><p class="w-75">A multicentre RCT compared rivaroxaban with dalteparin in 203 patients with active cancer who had symptomatic PE. It found rivaroxaban was associated with relatively low VTE recurrence but higher clinically relevant non-major bleeding compared with dalteparin. This is a rapidly evolving area with continuing developments in the evidence. [ASCO]</p></li>
                                             </ul>
                                             <p class="w-75"><strong>Evidence regarding treatment of cancer-related PE with fondaparinux is limited.</strong></p>
                                       </div>
                                    </div>
                                 </div>

                                     <h3>Severe renal impairment or established renal failure [NICE]</h3>
                                    <p class="w-75"><strong>Seek advice from a haematologist for these patients. Among the options suggested by NICE for this patient group are:</strong></p>
                                    <ul>
                                    <li><p class="w-75"><strong>LMWH </strong>with dose adjustments based on an anti-Xa assay.This should be overlapped with warfarin.[NICE]</p></li>
                                    </ul>
                                    <p class="w-75"><strong>OR</strong></p>
                                    <ul>
                                    <li><p class="w-75"><strong>Rivaroxaban, edoxaban, and apixaban</strong> can be used with caution and at a reduced dose in patients with renal impairment.[NICETA287][TA354][TA341]</p></li>
                                    </ul>

                                    <div id="tip_pitfall" class="card card-inverse mb-4">
                                          <div class="card-block">
                                             
                                             <h3 class="card-title"><p class="w-75">Warfarin is safe to use in patients with renal impairment with no dose adjustments necessary. However, monitor the INR more carefully in these patients.</p></h3>
                                          </div>
                                       </div>
                                        <h3>Hepatic impairment</h3>
                                       <p class="w-75"><strong>Seek haematology advice for all patients with hepatic impairment.</strong></p>
                                        <h3>Patients with increased risk of bleeding</h3>
                                       <p class="w-75"><strong>Seek advice from a haematologist for these patients. NICE suggests the following options:</strong></p>
                                       <ul>
                                       <li><p class="w-75"><strong>Use UFH but consider consultation with a haematologist prior to starting treatment</strong>. UFH has a short half-life, is easy to monitor, and is readily reversed by protamine. [NICE]</p></li>
                                       <li><p class="w-75"><strong>Consider fondaparinux</strong> for patients with suspected or confirmed heparin-induced thrombocytopenia (HIT) as it appears to be effective in these patients and carries a low risk of inducing HIT. [NICE]</p></li>
                                       </ul>
                                        <h3>Recurrent PE</h3>
                                       <p class="w-75"><strong>Seek advice from haematology for any patient who has a recurrent PE despite adequate anticoagulation treatment. </strong>Options may include: [ACCP]</p>
                                       <ul>
                                       <li><p class="w-75"><strong>Switching treatment to LMWH</strong> at least temporarily (for at least one month) if the patient was taking warfarin or a DOAC when the recurrent PE occurred.</strong></p></li>
                                       </ul>
                                       <p class="w-75"><strong>OR</strong></p>
                                       <ul>
                                       <li><p class="w-75"><strong>Increasing the dose of LMWH</strong> by one-quarter to one-third if the patient was already taking LMWH when the recurrent PE occurred. [ACCP]</strong></p></li>
                                       </ul>
                                       <p class="w-75"><strong>Recurrent PE is unusual among patients receiving therapeutic-dose anticoagulation. [KEARON]</strong></p>
                                       <ul>
                                       <li><p class="w-75"><strong>Check concordance with the anticoagulation regimen and consider the possibility of an underlying malignancy.</strong></p></li>
                                       </ul>

                                       <div class="evidence-accordion">
                                          <div class="option">
                                             <input type="checkbox" id="toggle9" class="toggle" />
                                             <label class="title" for="toggle9">
                                                <span class="material-icons"><span></span></span>
                                                <span class="title">Evidence: Risk of recurrent VTE  after discontinuation of anticoagulation</span>
                                             </label>
                                             <div class="content">
                                                <p class="w-75"><strong>The risk for recurrent VTE after discontinuation of anticoagulation is related to the features of the first VTE event. </strong></p>
                                                <ul>
                                                <li><p class="w-75">A study that followed patients with a first episode of acute PE found that the recurrence rate after discontinuation of treatment was approximately 2.5% per year after PE associated with reversible risk factors compared with 4.5% per year after unprovoked PE.[ZONZIN]</p></li>
                                                <li><p class="w-75">Similar observations were made in other prospective studies in patients with DVT.[LOOGNA]</p></li>
                                                </ul>
                                                <p class="w-75"><strong>R</strong><strong>ecurrence rates may be up to 10% in the first year after withdrawal of anticoagulant treatment. </strong></p>
                                                <ul>
                                                <li><p class="w-75">For patients with provoked PE, anticoagulation for 3 months is preferable to a shorter period. Treatment for longer than 3 months is generally not recommended, provided that the transient risk factor no longer exists.[ESC][ZONZIN]</p></li>
                                                </ul>
                                             </div>
                                          </div>
                                       </div>
                                       

                     </div>
                     <div id="9" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse"
                           data-target="#collapseTest-9">
                           <h3>Primary reperfusion in patients with shock or hypotension</h3>
                        </div>
                     </div>
                     <div id="collapseTest-9" class="row rowDetails p-3 collapse">
                        <p class="w-75"><strong>Emergency primary reperfusion is indicated for any haemodynamically unstable patient with: [ESC]</strong></p>
                        <ul>
                        <li><p class="w-75"><strong>PE confirmed on CTPA</strong></p></li>
                        <li><p class="w-75"><strong>Suspected PE and unequivocal signs of RV dysfunction on echocardiography</strong> (if CTPA is not immediately available and/or the patient is too unwell to undergo CTPA).</p></li>
                        </ul>
                        <p class="w-75"><strong>Thrombolysis is the first-line intervention for most patients </strong></p>
                        <ul>
                        <li><p class="w-75">Surgical embolectomy or catheter-directed therapy are alternatives. [ESC]</p></li>
                        </ul>
                        <h2>Thrombolysis</h2>
                        <p class="w-75">Ideally, PE should be confirmed by computed tomographic pulmonary angiography (CTPA) prior to thrombolysis. [BARCO] In practice, <strong>thrombolysis is typically started on clinical grounds if a high-risk PE is highly suspected and there is evidence of right ventricular dysfunction on echocardiography. </strong></p>
                        <p class="w-75"><strong>Administer thrombolysis (unless contraindicated) to any patient with SBP &lt;90 mmHg or who has other signs of shock. </strong></p>
                        <ul>
                        <li><p class="w-75">Systemic thrombolysis is associated with <strong>lower all-cause mortality</strong> in these patients when compared with UFH alone. [ESC] [CARDIO]</p></li>
                        </ul>
                        <p class="w-75"><strong>Give thrombolysis as soon as possible and certainly within 48 hours of symptom onset to ensure optimum benefit.</strong> [ESC]</p>
                        <p class="w-75"><strong>Select an accelerated regimen administered over 2 hours.</strong></p>
                        <ul>
                        <li><p class="w-75">These regimens are preferred to prolonged infusions over 12-24 hours. The European Society of Cardiology guideline lists <strong>alteplase, streptokinase, and urokinase</strong> as approved thrombolytics for acute PE. [ESC] Alteplase and higher-dose streptokinase are administered over 2 hours; whereas, lower-dose streptokinase and urokinase are administered over 12 to 24 hours.</p></li>
                        </ul>
                        <p class="w-75"><strong>Give a vasopressor such as adrenaline (epinephrine) or noradrenaline (norepinephrine), or an inotrope such as dobutamine if SBP remains &lt;90 mmHg after thrombolysis</strong>[ESC]</p>
                        <ul>
                        <li><p class="w-75">In haemodynamically unstable patients, use of a vasopressor or an inotrope is often needed in parallel with reperfusion. [ESC]</p></li>
                        </ul>
                        
                        <div class="evidence-accordion">
                           <div class="option">
                              <input type="checkbox" id="toggle10" class="toggle" />
                              <label class="title" for="toggle10">
                                 <span class="material-icons"><span></span></span>
                                 <span class="title">Evidence: Most patients with high-risk PE respond to early thrombolysis</span>
                              </label>
                              <div class="content">
                                 <p class="w-75"><strong>Thrombolysis in the treatment of acute haemodynamically unstable PE has been shown to </strong><strong>restore pulmonary perfusion more rapidly than anticoagulation with UFH alone.</strong></p>
                                 <ul>
                                 <li><p class="w-75">An RCT of 36 patients concluded that use of alteplase, compared with heparin, resulted in a greater and faster improvement of angiographic and hemodynamic variables. However, the high frequency of bleeding observed with alteplase in this trial suggests that patients should be carefully selected before thrombolytic therapy is given. [PENGO]</p></li>
                                 </ul>
                                 <p class="w-75"><strong>Overall, &gt;90% of patients appear to respond favourably to thrombolysis</strong>.</p>
                                 <ul>
                                 <li><p class="w-75">This was demonstrated in a prospective single-centre registry of 488 PE patients who underwent thrombolysis as judged by clinical and echocardiographic improvement within 36 hours. [BLONDE]</p></li>
                                 <li><p class="w-75">Among the minority of patients with high-risk PE who did not respond to thrombolysis, rescue surgical embolectomy led to lower mortality rates and fewer recurrent PEs when compared with repeat thrombolysis.</p></li>
                                 </ul>
                                 <p class="w-75"><strong>Thrombolysis has greatest benefit when given early after symptom onset.</strong></p>
                                 <ul>
                                 <li><p class="w-75">An overview of 308 PE patients from 5 clinical trials who underwent thrombolysis for PE showed an inverse relation between duration of symptoms and improvement on post-treatment lung scan reperfusion scores. For each additional day of symptoms before thrombolysis, there was a decrease of 0.8% in lung tissue reperfusion. Similarly, on angiography, less clot lysis was observed immediately after thrombolysis in the group with the longest duration of symptoms compared with those with the shortest symptom duration.</p></li>
                                 <li><p class="w-75">However the authors concluded that thrombolysis may still have some benefit in patients who have had symptoms for 6 to 14 days. [AM]</p></li>
                                 </ul>
                              </div>
                           </div>
                        </div>
                        
                        <div class="evidence-accordion">
                           <div class="option">
                              <input type="checkbox" id="toggle11" class="toggle" />
                              <label class="title" for="toggle11">
                                 <span class="material-icons"><span></span></span>
                                 <span class="title">Evidence: Choice of vasopressor is based on limited evidence</span>
                              </label>
                              <div class="content">
                                    <p class="w-75"><strong>Adrenaline combines the beneficial properties of noradrenaline (vasoconstriction with increased right ventricular perfusion, positive inotropy) and dobutamine (positive inotropy), but without the vasodilatory effects associated with the latter.</strong> [ESC]</p>
                                    <ul>
                                    <li><p class="w-75">A small prospective, descriptive study of patients with RV failure and shock demonstrated that during adrenaline infusion, mean arterial pressure (MAP), cardiac index (CI) and stroke volume index (SVI) were increased and right ventricular ejection fraction (RVEF) improved.</p></li>
                                    <li><p class="w-75">Another small study showed that adrenaline improved cardiac output in patients with shock without having a detrimental effect on pulmonary vascular resistance. [BARRINGTON]</p></li>
                                    </ul>
                                    <p class="w-75"><strong>Evidence suggests noradrenaline appears to improve RV function through its inotropic effect, as well as improving coronary perfusion by raising systemic pressure.</strong></p>
                                    <ul>
                                    <li><p class="w-75">However, noradrenaline increases pulmonary vascular resistance and no conclusive data are available regarding its potential use in PE. [PREWITT]</p></li>
                                    </ul>
                                    <p class="w-75"><strong>The use of dobutamine (an inotrope) and/or dopamine may be considered for patients with PE, low cardiac index, and normal BP based on the results of some studies. [ESC]</strong></p>
                                    <ul>
                                    <li><p class="w-75">Dobutamine enhances contractility with an increase in stroke volume and cardiac output. However, raising the cardiac index above physiological values may aggravate the ventilation&ndash;perfusion mismatch by further redistributing ﬂow from (partly) obstructed to unobstructed vessels. [DIS][ESC]</p></li>
                                    </ul>
                              </div>
                           </div>
                        </div>

                        <h3>Contraindications to thrombolysis</h3>
                        <p class="w-75"><strong>Seek haematology advice if a patient with high-risk PE who is haemodynamically unstable has any contraindications to thrombolysis. These are: [ESC]</strong></p>
                        <ul>
                        <li><p class="w-75"><strong>Absolute contraindications:</strong>
                           <ul>
                           <li><p class="w-75">haemorrhagic stroke or stroke of unknown origin at any time</p></li>
                           <li><p class="w-75">ischaemic stroke in the preceding 6 months</p></li>
                           <li><p class="w-75">central nervous system damage or neoplasms</p></li>
                           <li><p class="w-75">recent major trauma/surgery/head injury (in the preceding 3 weeks)</p></li>
                           <li><p class="w-75">gastrointestinal bleeding within the last month</p></li>
                           <li><p class="w-75">known bleeding risk.</p></li>
                           </ul>
                        </p></li>
                        <li><p class="w-75"><strong>Relative contraindications:</strong>                        
                           <ul>
                              <li><p class="w-75">transient ischaemic attack in the preceding 6 months</p></li>
                              <li><p class="w-75">oral anticoagulant therapy</p></li>
                              <li><p class="w-75">pregnancy or within 1 week postnatally</p></li>
                              <li><p class="w-75">traumatic resuscitation (in relation to this episode of PE)</p></li>
                              <li><p class="w-75">refractory hypertension (SBP &gt;180 mmHg)</p></li>
                              <li><p class="w-75">advanced liver disease</p></li>
                              <li><p class="w-75">infective endocarditis</p></li>
                              <li><p class="w-75">active peptic ulcer</p></li>
                           </ul>
                        </p></li>
                        </ul>

                        <div id="tip_pitfall" class="card card-inverse mb-4">
                              <div class="card-block">
                                 
                                 <h3 class="card-title"></h3>
                                 <ul>
                                    <li><p class="w-75">In practice, almost any contraindication to thrombolysis should be considered only relative in high-risk patients who present with haemodynamic instability.</p></li>
                                    <li><p class="w-75">This is because the mortality risk from high-risk PE is so high that it is likely to outweigh any bleeding risk from thrombolysis in this patient group. [ESC]</p></li>
                                    <li><p class="w-75">A decision on the risk-benefit balance should be made by a haematologist.</p></li>
                                 </ul>
                              </div>
                           </div>

                           
                        <div class="evidence-accordion">
                           <div class="option">
                              <input type="checkbox" id="toggle12" class="toggle" />
                              <label class="title" for="toggle12">
                                 <span class="material-icons"><span></span></span>
                                 <span class="title">Evidence: Thrombolysis carries a significant risk of major bleeding, including  intracranial bleeding</span>
                              </label>
                              <div class="content">
                                 <ul>
                                 <li><p class="w-75">Analysis of pooled data from trials using various thrombolytic agents and regimens reported intracranial bleeding rates between 1.9% and 2.2%. [PARKER][CALIFF]</p></li>
                                 <li><p class="w-75">Increasing age and the presence of comorbidities have been associated with a higher risk of bleeding complications.[MIKKOLA]</p></li>
                                 <li><p class="w-75">The PEITHO trial showed a 2% incidence of haemorrhagic stroke after thrombolytic treatment with tenecteplase (versus 0.2% in the placebo arm) in patients with intermediate-high-risk PE. Major non-intracranial bleeding events were also increased in the tenecteplase group, compared with placebo (6.3% vs. 1.5%; <em>P &lt;</em> 0.001). [VICAUT] Note that tenecteplase is not licensed for use in PE.</p></li>
                                 <li><p class="w-75">These results underline the need to improve the safety of thrombolytic treatment in patients at increased risk of intracranial or other life-threatening bleeding.</p></li>
                                 <li><p class="w-75">A strategy using reduced-dose alteplase appeared to be safe in the setting of &lsquo;moderate&rsquo; PE in a study that included 121 patients,[SHARIFI] and another trial on 118 patients with haemodynamic instability or &lsquo;massive pulmonary obstruction&rsquo; reported similar results. [WU]</p></li>
                                 <li><p class="w-75">An alternative approach may consist of local, catheter-delivered, ultrasound-assisted thrombolysis using small doses of a thrombolytic agent. [ESC]</p></li>
                                 </ul>
                              </div>
                           </div>
                        </div>
                        <p class="w-75"><strong>Do not give routine thrombolysis to patients who have SBP &gt;90 mmHg but have significant evidence of cardiopulmonary deterioration</strong>. [ESC] [SPRINGER]</p>
                        <ul>
                        <li><p class="w-75"><strong>Routine thrombolysis is not recommended in most major guidelines for this intermediate-risk group even if signs of both right ventricular dysfunction and myocardial injury (positive cardiac biomarkers) are initially present.</strong></p></li>
                        <li><p class="w-75">In these patients, use of systemic thrombolysis is associated with a <strong>mortality benefit</strong> but it significantly <strong>increases the risk of bleeding</strong>, including intracranial haemorrhage. [CARDIO]</p></li>
                        <li><p class="w-75">Patients in this intermediate risk group should receive anticoagulation and be monitored closely over at least 48 to 72 hours. Rescue thrombolysis should be considered if there are clinical signs of haemodynamic decompensation and the benefits/risks of thrombolysis have been weighed up by a specialist after taking account of the patient&rsquo;s comorbidities. [ESC][CHEST]</p></li>
                        </ul>

                        <div class="evidence-accordion">
                           <div class="option">
                              <input type="checkbox" id="toggle13" class="toggle" />
                              <label class="title" for="toggle13">
                                 <span class="material-icons"><span></span></span>
                                 <span class="title">Evidence: Evidence does not support the routine use of thrombolysis in patients with intermediate-risk PE</span>
                              </label>
                              <div class="content">
                                    <p class="w-75"><strong>Current European guidelines do not recommend giving thrombolysis routinely in patients with intermediate-risk PE. Evidence suggests it carries an unacceptably high bleeding risk in this group. </strong>[ESC][CHEST] .</p>
                                    <ul>
                                    <li><p class="w-75">The intermediate-risk group is defined by a PESI score of III-V or an sPESI score &ge;1. (see Risk Stratification below)</p></li>
                                    <li><p class="w-75">The international PEITHO (Pulmonary Embolism Thrombolysis) trial compared a single intravenous bolus of tenecteplase plus heparin with placebo plus heparin in 1,006 patients with confirmed PE, right ventricular dysfunction detected by echocardiography or CT, and a positive troponin I or T test.</p></li>
                                    <li><p class="w-75">In the thrombolysis group, haemodynamic decompensation/collapse or death within 7 days occurred less frequently than in the group receiving heparin alone.</p></li>
                                    <li><p class="w-75">However, in the thrombolysis group compared with the placebo group, there was also a higher incidence of haemorrhagic stroke (2.0% vs 0.2%) and major non-intracranial bleeding (6.3% vs 1.5%).</p></li>
                                    </ul>
                              </div>
                           </div>
                        </div>

                        <h2>Surgical embolectomy or catheter-directed therapy</h2>
                        <p class="w-75"><strong>The use of these will depend on local expertise and availability. According to the European Society of Cardiology (ESC) guideline, they are indicated in the following circumstances: </strong>&nbsp;[ESC]</p>
                        <ul>
                        <li><p class="w-75">Patients who are unable to receive thrombolytic therapy because of bleeding risk</p></li>
                        <li><p class="w-75">Insufficient time for effective systemic thrombolysis</p></li>
                        <li><p class="w-75">Failed thrombolysis</p></li>
                        </ul>
                        <p class="w-75"><strong>Surgical pulmonary embolectomy</strong></p>
                        <ul>
                        <li><p class="w-75">Although this is rarely performed in the UK, the ESC guideline recommends it as an option. [ESC]</p></li>
                        <li><p class="w-75">The guideline states that is technically a relatively simple operation although in practice it is normally only undertaken in specialist cardiothoracic centres. [ESC]</p></li>
                        </ul>
                        <p class="w-75"><strong>Percutaneous catheter-directed therapy</strong></p>
                        <ul>
                        <li><p class="w-75">Catheter-directed therapy uses a lower dose of thrombolytic drug (approximately one third of full-dose systemic thrombolysis) and is believed to reduce the risks of bleeding at remote sites(e.g. intracranial or gastrointestinal). [KEARON]</p></li>
                        <li><p class="w-75">For patients with absolute contraindications to thrombolysis, interventional options include: [ESC]
                              <ul>
                                    <li><p class="w-75">thrombus fragmentation with pigtail or balloon catheter,</p></li>
                                    <li><p class="w-75">rheolytic thrombectomy with hydrodynamic catheter devices,</p></li>
                                    <li><p class="w-75">suction thrombectomy with aspiration catheters</p></li>
                                    <li><p class="w-75">rotational thrombectomy.</p></li>
                                    </ul>
                        </p></li>
                        
                        <li><p class="w-75">For patients with relative contraindications to thrombolysis, interventional options include: [ESC]
                              <ul>
                                    <li><p class="w-75">catheter-directed thrombolysis</p></li>
                                    <li><p class="w-75">pharmacomechanical thrombolysis</p></li>
                                    </ul>
                        </p></li>
                        
                        </ul>

                        <div class="evidence-accordion">
                           <div class="option">
                              <input type="checkbox" id="toggle14" class="toggle" />
                              <label class="title" for="toggle14">
                                 <span class="material-icons"><span></span></span>
                                 <span class="title">Evidence: Surgical pulmonary embolectomy and catheter-directed therapy outcomes</span>
                              </label>
                              <div class="content">
                                 <p class="w-75"><strong>There is no comparative data to guide the primary management of patients with high-risk (massive) PE and a strong contraindication to systemic thrombolysis and therefore management will depend on local options and expertise</strong>.</p>
                                 <ul>
                                 <li><p class="w-75">However, some small studies have looked at outcomes from surgical pulmonary embolectomy and catheter-directed therapy.</p></li>
                                 <li><p class="w-75">Mortality rates following pulmonary embolectomy range from 4% to 27%. [FUKUDA] In a small cohort of patients who underwent surgical pulmonary embolectomy for acute high-risk (massive) pulmonary thromboembolism, the 10-year survival rate was 84%. [FUKUI]</p></li>
                                 <li><p class="w-75">A meta-analysis of non-randomised trials of catheter-directed therapies reported a clinical success rate of 87% with an associated risk of major and minor complications of 2% and 8%, respectively [KUO],</p></li>
                                 <li><p class="w-75">The extent of early RV recovery after low-dose catheter-directed thrombolysis appears comparable to that after standard-dose systemic thrombolysis whereas anticoagulation with heparin alone has little effect on improvement of RV size and performance within the first 24&ndash;48 hours.</p></li>
                                 <li><p class="w-75">In a randomized, controlled clinical trial of 59 intermediate-risk patients, when compared with treatment by heparin alone, catheter-directed ultrasound-accelerated thrombolysis&mdash;administering 10 mg of alteplase per treated lung over 15 hours&mdash;significantly reduced the subannular RV/LV dimension ratio between baseline and 24-hour follow-up without an increase in bleeding complications [TIEDE] [BOLUS][KUCHER]</p></li>
                                 </ul>
                              </div>
                           </div>
                        </div>

                        <h2>Venous filters</h2>
                        <p class="w-75"><strong>Consider a venous filter for any patient with confirmed PE who is deemed unsuitable for anticoagulation after discussion with a haematologist - in practice, they are rarely used outside the US. [BARCO] </strong></p>
                        <ul>
                        <li><p class="w-75"><strong>A retrievable venous filter should be used where possible</strong> and should be removed as soon as the reason for the absolute contraindication to anticoagulation has been resolved. [ESC][ACP][ACIR]</p></li>
                        <li><p class="w-75">The filter is normally placed in the infrarenal portion of the inferior vena cava (IVC). [BARCO]</p></li>
                        </ul>
                        <p class="w-75"><strong>The role of venous filters in PE remains controversial.</strong></p>
                        <ul>
                        <li><p class="w-75">The European Society of Cardiology recommends venous filters in: [ESC]<ul>
                              <li><p class="w-75">patients with confirmed acute PE who have an absolute contraindication to anticoagulation.</p></li>
                              <li><p class="w-75">patients with confirmed recurrent PE despite adequate anticoagulation treatment.</p></li>
                              </ul></p></li>
                        
                        <li><p class="w-75">Their use is increasing rapidly in the US and the The American Society for Interventional Radiology has recommended a significantly longer list of indications for venous filter then the European Society of Cardiology. [ACRSIR]</p></li>
                        </ul>
                        <p class="w-75"><strong>Complications associated with permanent venous filters are common and include</strong>: [HANN] [FAILLA]</p>
                        <ul>
                        <li><p class="w-75">Early<ul>
                              <li><p class="w-75">insertion site thrombosis (10%)</p></li>
                              <li><p class="w-75">pericardial tamponade (when placing filter in the superior vena cava.)</p></li>
                              </ul></p></li>
                        
                        <li><p class="w-75">Late (more common)<ul>
                              <li><p class="w-75">recurrent DVT (20%)</p></li>
                              <li><p class="w-75">post-thrombotic syndrome (40%)</p></li>
                              <li><p class="w-75">occlusion of the IVC (regardless of use and duration of anticoagulation)
                                    <ul>
                                          <li><p class="w-75">22% at 5 years</p></li>
                                          <li><p class="w-75">33% at 9 years</p></li>
                                          </ul>
                              </p></li>
                           </ul></p></li>
                        </ul>

                        <div id="tip_pitfall" class="card card-inverse mb-4">
                              <div class="card-block">
                                 
                                 <h3 class="card-title">In clinical practice venous filters are not commonly used in the UK or Europe.</h3>
                                 <ul>
                                 <li><p class="w-75">It is common practice to seek advice from a haematologist in patients with contraindications to anticoagulation.</p></li>
                                 <li><p class="w-75">Many of these patients - even those with apparent absolute contraindications - may still be able to have a different or altered dose of anticoagulation with an acceptable risk-benefit balance and this is usually preferred to a venous filter.</p></li>
                                 </ul>
                              </div>
                           </div>



                           <div class="evidence-accordion">
                                 <div class="option">
                                    <input type="checkbox" id="toggle15" class="toggle" />
                                    <label class="title" for="toggle15">
                                       <span class="material-icons"><span></span></span>
                                       <span class="title">Evidence: The evidence shows varied outcomes from use of  venous filters in PE</span>
                                    </label>
                                    <div class="content">
                                          <p class="w-75"><strong>The use of venous filters is controversial and there is limited evidence to support recommendations about their use in clinical practice. For use in acute PE the evidence shows varied outcomes.</strong></p>
                                          <ul>
                                             <li><p class="w-75">There have only been two RCTs performed in Europe.</p></li>
                                             <li><p class="w-75">The first, PREPIC (Pr&eacute;vention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group), randomized 400 patients who suffered acute VTE to anticoagulation alone or anticoagulation and a permanent inferior vena cava filter (IVCF). Follow up at 8 years showed that while IVC filters reduced the risk of recurrent PE, they did not prevent death, and more DVTs occurred in patients who received these devices.</p></li>
                                             <li><p class="w-75">The second study, PREPIC 2, randomised 399 patients with PE associated with DVT to anticoagulation alone or anticoagulation plus a retrievable IVCF. All the patients had at least one "high-risk" feature (age &gt;75 years old, active cancer, chronic cardiac or respiratory insufficiency, ischemic stroke with leg paralysis within 6 months, either iliocaval or bilateral DVT, or a sign of right ventricular strain or myocardial injury). Again, use of venous filter did not show any mortality benefit nor did they result in fewer symptomatic PEs during the first 3 months of follow-up.</p></li>
                                             <li><p class="w-75">On the other hand observational studies from the US, analyzing almost 298,000 filter implantations, &nbsp;suggest that insertion of a venous filter might reduce PE-related mortality rates in the acute phase, with benefit possibly coming at the cost of an increased risk of recurrence of VTE. [MURIEL]</p></li>
                                             </ul>
                                    </div>
                                 </div>
                              </div>

                     </div>
                     <div id="10" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse"
                           data-target="#collapseTest-10">
                           <h3>Risk stratification</h3>
                        </div>
                     </div>
                     <div id="collapseTest-10" class="row rowDetails p-3 collapse">
                        <ul>
                           <li><p class="w-75"><strong>Risk stratify stable patients using the Pulmonary Embolism Severity Index (PESI) score or the simplified Pulmonary Embolism Severity Index (sPESI) score</strong>. <strong>[LINK TO PESI scoring calculator AND sPESI scoring calculator EBM calc] </strong>
                              <ul>
                                 <li><p class="w-75">The PESI/sPESI risk score can be used to risk stratify haemodynamically stable patients to: [ESC] [BTS]</p></li>
                                    <ul>
                                    <li><p class="w-75"><strong>identify an intermediate-risk group</strong> who need close monitoring (PESI III-IV or sPESI &ge;1)</p></li>
                                    <li><p class="w-75"><strong>select low-risk patients who can be considered for outpatient management</strong> or early discharge (PESI I-II or sPESI 0)</p></li>
                              </ul>
                           </p></li>
                           <li><p class="w-75">The <strong>sPESI is non-inferior to the PESI </strong>in predicting 30-day mortality. [BTS]</p></li>
                           </ul>
                           
                           <p class="w-75"><strong>Do not use PESI/sPESI scoring in:</strong></p>
                           <ul>
                           <li><p class="w-75"><strong><strong>Patients with hypotension or shock. </strong>All such patients are high-risk and must be managed accordingly with emergency primary reperfusion and anticoagulation<strong>.</strong></strong></p></li>
                           </ul>
                           <ul>
                           <li><p class="w-75"><strong>Pregnant women</strong></p></li>
                           </ul>

                           <h2><strong>Intermediate-risk PE</strong></h2>
                           <p class="w-75"><strong>A haemodynamically stable patient is at intermediate-risk of a poor outcome if they have a PESI score of III-IV or an sPESI score &ge;1. [ESC] [BTS]</strong></p>
                           <p class="w-75"><strong>Start these patients on anticoagulation and monitor them very closely as they are at risk of deterioration</strong>.</p>
                           <ul>
                           <li><p class="w-75">If they become haemodynamically unstable or are clinically deteriorating they will need reperfusion therapy (usually rescue thrombolysis). [ESC]</p></li>
                           <li><p class="w-75"><strong>Rescue thrombolysis may be indicated in </strong>intermediate-risk patients, and in patients with other clinical features of cardiopulmonary impairment (e.g., elevated heart rate, respiratory rate, jugular venous pressure) who have started anticoagulant therapy, and:<ul>
                           <li><p class="w-75">are clinically deteriorating, but have not yet developed hypotension</p></li>
                           <li><p class="w-75">are exhibiting signs of haemodynamic decompensation (e.g. SBP &lt;90 mmHg for at least 15 minutes, or drop of SBP by at least 40 mmHg for at least 15 minutes with signs of end organ hypoperfusion). [ESC]</p></li>
                           </ul></p></li>
                           </ul>
                           
                           <p class="w-75"><br /><strong>Consider early discharge </strong>once a patient admitted with an intermediate-risk PE improves sufficiently to meet the criteria for low-risk PE (PESI I-II or sPESI 0). [BTS]</p>
      
                           
                           <div id="tip_pitfall" class="card card-inverse mb-4">
                              <div class="card-block">
                                 
                                 <h3 class="card-title">The 2014 European Society of Cardiology guideline suggests further risk stratification of intermediate-risk patients by measuring cardiac markers if there is evidence of RV dysfunction on either CTPA or echo.</h3>
                                 <ul>
                                 <li><p class="w-75">Patients are classified as &lsquo;intermediate-high&rsquo; risk if there is RV dysfunction AND the cardiac biomarker is elevated and as &lsquo;intermediate-low&rsquo; risk if there is either an elevated cardiac biomarker OR evidence of RV dysfunction. [ESC]</p></li>
                                 </ul>
                                 <p class="w-75"><strong>However, this practice is not followed in all centres so check local protocols.</strong></p>
                              </div>
                           </div>

                           <h2>Low-risk PE</h2>
                           <p class="w-75"><strong>A patient is considered low-risk if they have a PESI score of I-II or an sPESI score of 0. [ESC] [BTS]</strong></p>
                           <p class="w-75"><strong>Consider outpatient management in patients who are classified as low risk</strong>.</p>
                           <ul>
                           <li><p class="w-75">PE does not need to be confirmed on CTPA prior to discharge but it should be performed within 24 hours (if available). [BTS]</p></li>
                           </ul>
                           <p class="w-75"><strong>Assessment of RV size/function on CTPA or echocardiography is not essential to confirm a patient as low-risk and suitable for outpatient management </strong>[BTS]</p>
                           <ul>
                           <li><p class="w-75">The 2018 British Thoracic Society (BTS) guideline states that<strong> echocardiography does not increase the predictive power of validated risk scores</strong> such as PESI/sPESI or HESTIA.</p></li>
                           <li><p class="w-75">It recommends considering measurement of cardiac biomarkers (high sensitivity troponin, BNP or NT-proBNP) only in patients who had evidence of RV strain on CTPA/echo if performed during diagnostic work-up. <ul>
                           <li><p class="w-75">If these are normal the patient can be considered for discharge. If they are elevated they should be admitted for observation. [BTS]</p></li>
                           </ul></p></li>
                          
                           </ul>
                           <p class="w-75"><strong>Do not discharge any patient with a low-risk sPESI score who meets one or more of these exclusion criteria:</strong> [BTS]</p>
                           <ul>
                           <ul>
                           <li><p class="w-75">Haemodynamic instability (HR &gt;110 bpm; SBP &lt;100 mmHg.</p></li>
                           <li><p class="w-75">requirement for inotropes and critical care.</p></li>
                           <li><p class="w-75">requirement for thrombolysis or embolectomy.</p></li>
                           <li><p class="w-75">Oxygen saturations &lt;90% on air.</p></li>
                           <li><p class="w-75">Active bleeding or risk of major bleeding (e.g., recent gastrointestinal bleed or surgery, previous intracranial bleeding, uncontrolled hypertension).</p></li>
                           <li><p class="w-75">On full-dose anticoagulation at the time of the PE.</p></li>
                           <li><p class="w-75">Severe pain (e.g., requiring opioid analgesics).</p></li>
                           <li><p class="w-75">Other medical comorbidities requiring hospital admission.</p></li>
                           <li><p class="w-75">Chronic kidney disease (CKD) stages 4 or 5 (estimated glomerular filtration rate (eGFR)&lt;30 mL/min) or severe liver disease.</p></li>
                           <li><p class="w-75">Heparin-induced thrombocytopenia (HIT) within the last year and where there is no alternative to repeating heparin treatment.</p></li>
                           <li><p class="w-75">Social reasons which may include inability to return home, inadequate care at home, lack of telephone communication, concerns over compliance, etc. [BTS]</p></li>
                           </ul>
                           </ul>

                           <div id="tip_pitfall" class="card card-inverse mb-4">
                              <div class="card-block">
                                 
                                 <h3 class="card-title">HESTIA is an alternative validated risk score that is less commonly used than sPESI to select patients suitable for outpatient management of PE.</h3>
                                 <ul>
                                 <li><p class="w-75">Check local guidelines to decide whether to use PESI/sPESI or HESTIA</p></li>
                                 </ul>
                                 <p class="w-75"><strong>If any one or more of the HESTIA exclusion criteria are present, the HESTIA score is considered positive and patients are deemed unsuitable for discharge [BTS]</strong></p>
                                 <p class="w-75"><strong>The HESTIA exclusion criteria are very similar to the BTS exclusion criteria for patients with a low-risk sPESI score:</strong></p>
                                 <ul>
                                 <li><p class="w-75"><strong>Haemodynamic instability</strong>
                                    <ul>
                                       <li><p class="w-75">SBP &lt;100 mmHg with heart rate &gt;100 bpm.</p></li>
                                       <li><p class="w-75">Condition requiring admission to an intensive care unit</p></li>
                                    </ul>
                                 </p></li>
                                 <li><p class="w-75"><strong>Thrombolysis or embolectomy indicated</strong></p></li>
                                 <li><p class="w-75"><strong>Active bleeding or high risk of bleeding</strong>
                                    <ul>
                                       <li><p class="w-75">Gastrointestinal bleeding in the preceding 14 days</p></li>
                                       <li><p class="w-75">Recent stroke (&lt;4 weeks ago).</p></li>
                                       <li><p class="w-75">Recent operation (&lt;2 weeks ago).</p></li>
                                       <li><p class="w-75">Bleeding disorder</p></li>
                                       <li><p class="w-75">Thrombocytopaenia (platelet count &lt;75 x 109/L)</p></li>
                                       <li><p class="w-75">Uncontrolled hypertension (SBP &gt;180 mmHg or DBP &gt;110 mmHg)</p></li>
                                    </ul>
                                 </p></li>
                                 <li><p class="w-75"><strong>Oxygen required for &gt;24 hours to maintain oxygen saturations &gt;90%</strong></p></li>
                                 <li><p class="w-75"><strong>PE diagnosed during anticoagulant treatment</strong></p></li>
                                 <li><p class="w-75"><strong>Severe pain requiring intravenous pain medication for &gt;24 hours.</strong></p></li>
                                 <li><p class="w-75"><strong>Medical or social reason for treatment in the hospital for &gt;24 hours</strong></p></li>
                                 <li><p class="w-75"><strong>Creatinine clearance &lt;30 mL/min</strong></p></li>
                                 <li><p class="w-75"><strong>Severe liver impairment (at discretion of clinician)</strong></p></li>
                                 <li><p class="w-75"><strong>Pregnancy</strong></p></li>
                                 <li><p class="w-75"><strong>Documented history of heparin-induced thrombocytopaenia.</strong></p></li>
                                 </ul>
                              </div>
                           </div>


                           <div class="evidence-accordion">
                              <div class="option">
                                 <input type="checkbox" id="toggle16" class="toggle" />
                                 <label class="title" for="toggle16">
                                    <span class="material-icons"><span></span></span>
                                    <span class="title">Evidence: sPESI and HESTIA risk scores perform similarly in identifying patients at risk of poor outcomes</span>
                                 </label>
                                 <div class="content">
                                       <ul>
                                          <li><p class="w-75">One study compared the Hestia criteria with sPESI for identifying patients at risk of 30-day mortality. Of 468 patients, 53% were identified as suitable for outpatient management using the Hestia exclusion criteria, with 59% deemed low risk according to sPESI. [ZONDAG]</p></li>
                                          <li><p class="w-75">Although both tools selected slightly different patients as low risk, they had similar overall outcomes, with 30-day adverse events (major bleeding, recurrent VTE or death) of 2.4% in the Hestia group and 2.2% in the sPESI low-risk group. sPESI performed slightly better than Hestia in testing.</p></li>
                                       </ul>
                                 </div>
                              </div>
                           </div>

                           <h3><strong>Discharging patients [BTS]</strong></h3>
                           <p class="w-75"><strong>Request a consultant review prior to discharge of any patient with confirmed or suspected PE.</strong></p>
                           <ul>
                           <li><p class="w-75">If no consultant is available, then patients may be reviewed by a senior trainee (ST3 or above; ST4 in the case of emergency medicine) by a staff grade or similar substantive career grade doctor, advanced nurse practitioner or clinical nurse specialist designated to undertake this role within the department with consultant advice available.</p></li>
                           </ul>
                           <p class="w-75"><strong>Provide verbal and written information on the signs and symptoms of recurrence, major bleeding and additional complications.</strong></p>
                           <ul>
                           <li><p class="w-75">There should also be an appropriate point of contact in the event of complications or concerns, both in and out of hours.</p></li>
                           </ul>
                           <p class="w-75"><strong>Organise a formal review (telephone/face to face) at least once during the first week</strong><strong>after discharge to ensure therapeutic compliance and check for any complications. </strong></p>
                           <p class="w-75"><strong>There should be local protocols and pathways in place for follow-up of all patients with PE, whether treated as an inpatient or outpatient. </strong></p>
                           <ul>
                           <li><p class="w-75">This should include assessment of ongoing symptoms (with further directed investigation as appropriate) and consideration of optimal duration/type of anticoagulation.</p></li>
                           </ul>
                           
                     </div>
                     <div id="11" class="row rowCondition">
                        <div class="accordion-toggle col-md-12" data-toggle="collapse"
                           data-target="#collapseTest-11">
                           <h3>Ongoing phase anticoagulation</h3>
                        </div>
                     </div>
                     <div id="collapseTest-11" class="row rowDetails p-3 collapse">
                           <p class="w-75"><strong>The standard duration of anticoagulation should cover at least 3 months</strong>. [ESC][NIHR]</p>
                           <ul>
                           <li><p class="w-75">Longer-term, sometimes indefinite, anticoagulation may be needed for secondary</p></li>
                           </ul>
                           <p class="w-75">prevention after weighing up the individual patient&rsquo;s risk of recurrence of PE versus bleeding risk.</p>
                           <ul>
                           <li><p class="w-75">All patients should be reviewed at 3 months as a minimum. [ESC]</p></li>
                           </ul>
                           <p class="w-75"><strong>Reassess the risks/benefits of continuing use of anticoagulation</strong> in all patients who receive extended treatment at periodic intervals (e.g., annually). There is no formally validated score for assessing bleeding risk in patients on anticoagulation for PE. [ACCP]</p>

                           <div class="evidence-accordion">
                              <div class="option">
                                 <input type="checkbox" id="toggle17" class="toggle" />
                                 <label class="title" for="toggle17">
                                    <span class="material-icons"><span></span></span>
                                    <span class="title">Evidence: Assessment of bleeding risk</span>
                                 </label>
                                 <div class="content">
                                    <p class="w-75"><strong>Many studies examining major bleeding rates have assessed these over 3 months or longer, whereas bleeding in the first 7&ndash;14 days may be more relevant for risks related to outpatient PE management.</strong></p>
                                    <ul>
                                    <li><p class="w-75">In the RIETE registry of 24,395 patients with VTE on anticoagulation, 2.24% had a major bleed and 0.55% had a fatal bleed during the first three months of anticoagulation. The RIETE investigators have derived and validated a score in patients with documented VTE to predict the risk of major bleeding within 3 months of anticoagulant therapy. [SUAREZ] On multivariate analysis, age &gt;75 years, recent bleeding, cancer, creatinine levels &gt;1.2 mg/dL, anaemia or PE itself were independently associated with an increased risk of major bleeding.</p></li>
                                    <li><p class="w-75">Another study compared the predictive value of the HEMORR2HAGES, HASBLED and ATRIA scores to the Kuijer and RIETE scores for the occurrence of major bleeding complications over a 30-day period in 448 consecutive patients with PE treated with warfarin. Most bleeding events (16/20) occurred in the first seven days after treatment initiation, with four bleeding complications between days 8 and 30. The predictive power of all five scores for bleeding was poor (c-statistics 0.57&ndash;0.64), both for the three-level and two-level score outcomes. No individual score was found to be superior. The HASBLED score had a good c-statistic for bleeding occurring after the first week of treatment (0.75, 95% CI 0.47 to 1.0). There are no studies deriving or validating an early bleeding risk score specifically for outpatient PE management. [DELLA]</p></li>
                                    </ul>
                                 </div>
                              </div>
                           </div>

                           <h2>uration of ongoing anticoagulation</h2>
                           <h3>Provoked PE</h3>
                           <p class="w-75"><strong>Anticoagulation can usually be stopped after 3 months following a provoked PE.[NICE] [ESC]</strong></p>
                           <ul>
                           <li><p class="w-75">A provoked PE is one associated with a transient risk factor that was present in the 3 months prior to the PE.</p></li>
                           <li><p class="w-75">Transient provoking risk factors include: surgery; trauma; significant immobility (bedbound, unable to walk unaided or likely to spend a substantial proportion of the day in bed or in a chair); pregnancy or puerperium; use of oral contraceptive/hormone replacement therapy.</p></li>
                           </ul>
                           <p class="w-75"><strong>Treatment for longer than 3 months is generally not recommended following a provoked PE, provided that the transient risk factor no longer exists.</strong> [ESC]</p>
                           <h3><strong>Unprovoked PE</strong></h3>
                           <p class="w-75"><strong>Anticoagulation is typically continued for &gt;3 months after an unprovoked PE [NICE] [ESC] </strong></p>
                           <ul>
                           <li><p class="w-75">An unprovoked PE is a PE in a patient who either<ul>
                           <li><p class="w-75">did NOT have a transient risk factor (as listed above) in the 3 months prior to the PE<br />OR</p></li>
                           <li><p class="w-75">has a provoking risk factor that persists (such as active cancer, thrombophilia, obesity).</p></li>
                           </ul></p></li>                           
                           </ul>


                           <div class="evidence-accordion">
                              <div class="option">
                                 <input type="checkbox" id="toggle18" class="toggle" />
                                 <label class="title" for="toggle18">
                                    <span class="material-icons"><span></span></span>
                                    <span class="title">Evidence:There is good evidence for longer duration of anticoagulation in unprovoked compared with provoked PE</span>
                                 </label>
                                 <div class="content">
                                       <p class="w-75"><strong>Clinical trials have evaluated various durations of anticoagulant treatment for VTE. The main findings of these studies were: </strong>[LARFARS][MED][KETIS][LOOG]</p>
                                       <ul>
                                       <li><p class="w-75">patients with PE should receive at least 3 months of anticoagulant treatment</p></li>
                                       <li><p class="w-75">the risk of recurrence if anticoagulants are stopped after 6 or 12 months can be expected to be similar to that after 3 months</p></li>
                                       <li><p class="w-75">indefinite treatment reduces the risk for recurrent VTE by about 90%, but this benefit is partially offset by a 1% or higher annual risk of major bleeding.</p></li>
                                       </ul>
                                       <p class="w-75"><strong>Evidence shows 3 months is the optimum duration of anticoagulation treatment in patients with a provoked PE. </strong></p>
                                       <ul>
                                       <li><p class="w-75">Four RCTs compared 3 months of anticoagulation with 6 to 12 months of therapy.[NINET][AGNELLI][PRAND] Meta-analysis of their findings found a similar risk of recurrence with 3 months compared to 6 to 12 months of therapy during 1 to 3 years of follow-up. [COMER] Analysis of individual patient data from these 4 trials, and another study that compared 3 months with 27 months of anticoagulation, also found no convincing increase in the risk of recurrence after treatment was stopped after 3 months. [GENT][PINEDE]</p></li>
                                       <li><p class="w-75">Five RCTs compared 4 to 6 weeks of anticoagulation with 3 to 6 months of anticoagulation. [HIRSH][LANCET] [NINET] [RHEDIN][SOFAST] Meta-analysis of their findings found that the shorter course of therapy was associated with about a twofold increase in recurrence during 9 to 24 months of follow-up. Analysis of individual patient data from 4 of these trialsdemonstrated that the risk of recurrence after stopping anticoagulant therapy was higher in patients who were treated for 4 to 6 weeks than in those treated for 3 months or more. [COMER] Furthermore, the excess recurrences with 4 to 6 weeks of therapy were confined in the first 6 months after stopping therapy and, in those with a DVT, the extra recurrences were in the same leg as the initial event. [PINEDE]</p></li>
                                       </ul>
                                       <p class="w-75"><strong>There is also growing evidence that longer anticoagulation in unprovoked PE is beneficial in order to reduce recurrence.</strong></p>
                                       <ul>
                                       <li><p class="w-75">Extended anticoagulation with warfarin has been shown to reduce recurrent VTE by approximately 90% based on meta-analysis of 4 studies, with about half of the recurrent episodes occurring in patients who had prematurely stopped therapy.[COMER][GENT][LARFARD][FARRAJ][COSMI]</p></li>
                                       <li><p class="w-75">Direct and indirect comparisons have found similar reductions in recurrent VTE with extended anticoagulation using dabigatran,[KAKKAR] rivaroxaban,[BRENNER] or apixaban.[BULLER][LEGAL]</p></li>
                                       <li><p class="w-75">Extended treatment with LMWH is also very effective, and is more effective than warfarin in cancer patients. [COMER][PINI][NIZAN]</p></li>
                                       </ul>
                                       <p class="w-75"><strong>Clinicians should balance the risk of bleeding against the risk of recurrence when making a decision about extended secondary prevention. </strong>[NIHR]</p>
                                 </div>
                              </div>
                           </div>

                           
                           <p class="w-75"><strong>Select either an oral DOAC or warfarin according to individual patient characteristics and preference (unless there are special considerations).</strong></p>
                           <h3>DOACs</h3>
                           <ul>
                           <li><p class="w-75"><strong>Any one of apixaban OR edoxaban OR rivaroxaban OR dabigatran can be chosen for ongoing anticoagulation depending on the patient&rsquo;s risk profile.[ESC][NICEAC]</strong>                           
                              <ul>
                                 <li><p class="w-75">If rivaroxaban or apixaban was used for acute phase anticoagulation, it can be continued.</p></li>
                                 <li><p class="w-75">If dabigatran or edoxaban is selected for ongoing anticoagulation, switch to dabigatran or edoxaban after at least 5 days of lead-in therapy with a parenteral anticoagulant. The parenteral anticoagulant should be stopped before starting dabigatran or edoxaban.[ESC][NICE]</p></li>
                              </ul>
                           </p></li>
                           <li><p class="w-75"><strong>In patients taking </strong><strong>apixaban or rivaroxaban who need ongoing anticoagulation &gt;6 months, it is becoming common practice to consider a dose reduction: </strong>[DOAC]
                              <ul>
                                 <li><p class="w-75">Continue with the full dose (i.e., rivaroxaban 20 mg/day or apixaban 10 mg/day) for a total of 6 months.</p></li>
                                 <li><p class="w-75">After six months:
                                    <ul>
                                       <li><p class="w-75">Continue the full dose after 6 months if the risk of VTE is felt to be high. <br /><strong>OR</strong></p></li>
                                       <li><p class="w-75">Consider halving the dose in patients in whom the risk of recurrent VTE if anticoagulation is stopped is thought to be similar to the risk of bleeding associated with continued anticoagulation.</p></li>
                                       </ul>
                                 </p></li>
                              </ul>
                           </p></li>
                           <li><p class="w-75"><strong>Emerging evidence suggests a low-dose regimen is as effective as a standard-dose regimen although there is no clear data to show a significant reduction in bleeding risk. [BULLER][WEITZ][LIU][GOTO]</strong></p></li>
                           </ul>


                           <div class="evidence-accordion">
                                 <div class="option">
                                    <input type="checkbox" id="toggle19" class="toggle" />
                                    <label class="title" for="toggle19">
                                       <span class="material-icons"><span></span></span>
                                       <span class="title">Evidence: DOACs have emerged as an equally effective and likely  safer option than heparin/warfarin</span>
                                    </label>
                                    <div class="content">
                                       <p class="w-75"><strong>There is now strong evidence that DOACs are non-inferior and have a favourable safety profile for management of PE when compared to either LMWH/warfarin or fondaparinux. [BTS]</strong></p>
                                       <ul>
                                       <li><p class="w-75">Results of the major trials using DOACs in the treatment of VTE indicate that these agents are non-inferior (in terms of efficacy) and possibly safer (particularly in terms of major bleeding) than the standard heparin/warfarin regimen. [WELLS][ESC][GALLUS] [BRENNER] [COCHRANE] [LIB]</p></li>
                                       <li><p class="w-75">A Cochrane review concluded there was [CCA LINK AS ABOVE]</p></li>
                                       <ul>
                                       <li><p class="w-75">no difference between dabigatran and the standard regimen in preventing recurrent VTE (OR 1.02, 95% CI 0.50 to 2.04), recurrent VTE (OR 0.93, 95% CI 0.52 to 1.66) and DVT (OR 0.79, 95% CI 0.29 to 2.13) or in causing major bleeding (OR 0.50, 95% CI 0.15 to 1.68)</p></li>
                                       <li><p class="w-75">no difference between the factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) compared to the standard regimen, in preventing recurrent VTE (OR 0.85, 95% CI 0.15 to 1.68), DVT (OR 0.72, 95% CI 0.39 to 1.32) and all-cause mortality (OR 1.16, 95% CI 0.59 to 1.62) or in causing major bleeding (OR 0.97, 95% CI 0.59 to 1.62).</p></li>
                                       </ul>
                                       <li><p class="w-75">High time in therapeutic range (TTR) values were achieved under warfarin treatment in all trials. On the other hand, the study populations included relatively young patients, very few of whom had cancer.</p></li>
                                       </ul>
                                       <p class="w-75"><strong>Experience with DOACs remains limited but they can be viewed as an alternative to standard treatment.</strong></p>
                                    </div>
                                 </div>
                              </div>
                              <h3><strong>Warfarin</strong></h3>
                              <p class="w-75"><strong>Offer warfarin within 24 hours of diagnosis and continue it for at least 3 months. </strong>[NICE]</p>
                              <ul>
                              <li><p class="w-75">It should be overlapped with a parenteral anticoagulant for at least 5 days or until the INR is &ge;2 for at least 24 hours (whichever is the longer).[NICE]</p></li>
                              </ul>
                              <p class="w-75">Standard-dose warfarin may be used for extended secondary prevention. [NIHR]</p>

                              <div class="evidence-accordion">
                                    <div class="option">
                                       <input type="checkbox" id="toggle20" class="toggle" />
                                       <label class="title" for="toggle20">
                                          <span class="material-icons"><span></span></span>
                                          <span class="title">Evidence: Warfarin for extended secondary prevention reduces mortality  but carries a risk of bleeding</span>
                                       </label>
                                       <div class="content">
                                             <ul>
                                                   <li><p class="w-75">A review of 22,000 patients demonstrated that standard-intensity warfarin reduced the all-cause mortality and reduced the risk of recurrent VTE compared to placebo or observation only when used for extended secondary prevention.</p></li>
                                                   <li><p class="w-75">However, warfarin also increased the risk of bleeding, with one major bleed for every 87 people treated. [NIHR]</p></li>
                                                   </ul>
                                       </div>
                                    </div>
                                 </div>

                                 <div class="evidence-accordion">
                                       <div class="option">
                                          <input type="checkbox" id="toggle21" class="toggle" />
                                          <label class="title" for="toggle21">
                                             <span class="material-icons"><span></span></span>
                                             <span class="title">Evidence:  Aspirin is ineffective for extended secondary prevention</span>
                                          </label>
                                          <div class="content">
                                             <ul>
                                                <li><p class="w-75">The 2014 European Society of Cardiology guideline recommends aspirin for extended secondary prevention for patients who refuse to take or are unable to tolerate any form of oral anticoagulants. [ESC]</p></li>
                                                <li><p class="w-75">However aspirin is not commonly used in the UK and a 2019 National Institute for Health Research review concluded that aspirin is ineffective in secondary prevention. [NIHR]</p></li>
                                                </ul>
                                          </div>
                                       </div>
                                    </div>

                                    <h2><strong>Special patient groups</strong></h2>

                                    <h3>Pregnancy</h3>
                                    <p class="w-75"><strong>Continue LMWH for the remainder of the pregnancy and for at least 6 weeks postnatally and until at least 3 months of treatment has been given in total. [RCOG]</strong></p>
                                    <ul>
                                    <li><p class="w-75">In the last month of pregnancy, or sooner if delivery appears imminent, women receiving either therapeutic or prophylactic anticoagulation may be converted from LMWH to UFH, which has a shorter half-life, is easy to monitor, and is readily reversed by protamine . [ACOG] [ESC]</p></li>
                                    </ul>
                                    <h3>Active cancer</h3>
                                    <p class="w-75"><strong>Continue LMWH for 6 months.</strong> At 6 months, assess the risks and benefits of continuing anticoagulation. [NICE] [ESC]</p>
                                    <h3><strong>Increased risk of bleeding</strong></h3>
                                    <p class="w-75"><strong>Seek advice from a haematologist </strong>in these patients. NICE guidelines recommend continuing UFH or fondaparinux for at least 3 months. [NICE]</p>
                                    <h3>Severe renal impairment or established renal failure</h3>
                                    <p class="w-75"><strong>Seek advice from a haematologist in these patients</strong>. NICE guidelines recommend continuing anticoagulation for at least 3 months. Among the options suggested by NICE for this patient group are:</p>
                                    <ul>
                                    <li><p class="w-75"><strong>LMWH </strong>with dose adjustments based on an anti-Xa assay. This should be overlapped with warfarin.<strong> [NICE]</strong></p></li>
                                    </ul>
                                    <p class="w-75"><strong>OR</strong></p>
                                    <ul>
                                    <li><p class="w-75"><strong>Rivaroxaban,edoxaban, and apixaban</strong> can be used with caution and at a reduced dose in patients with renal impairment.<strong>[NICETA287] [TA354][TA341]</strong></strong></p></li>
                                    </ul>
                                    <h3>Hepatic impairment</h3>
                                    <p class="w-75"><strong>Seek haematology advice for all patients with hepatic impairment.</strong></p>
                     </div>



                  </div>
               </div>
            </div>
         </div>




      </div>
      <!--END POCE -->
      <div class="card-block disclaimer">
         <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/"
                  target="_blank">disclaimer</a> </span></p>
      </div>
   </main>
   <script type="text/javascript" id="">
      (function () {
         var f = google_tag_manager["GTM-K3TZ3JV"].macro(4),
            b = google_tag_manager["GTM-K3TZ3JV"].macro(5),
            a = function (a, b, d) {
               var e = "",
                  c = new Date;
               d && (c.setTime(c.getTime() + 864E5 * d), e = "; expires\x3d" + c.toGMTString());
               document.cookie = a + "\x3d" + b + e + "; path\x3d/; domain\x3dbmj.com"
            };
         f ? "true" != b && ("justLoggedIn" == b ? a("loggedIn", "true", 2) : a("loggedIn", "justLoggedIn", 2)) : a(
            "loggedIn", "false", 2)
      })();
   </script>
   <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
   <script>
      /*<![CDATA[*/

      var messagesCountryCode = "en_GB";
      /*]]>*/
   </script>
   <aside id="panel-nhs" class="card-block">
      <div id="access" class="col-sm-6">
         <div class="row">
            <div class="col-md-6">
               <p>Access provided by:</p>
            </div>
            <div class="col-md-6">
               <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
            </div>
         </div>
      </div>
   </aside>
   <footer id="footer">
      <div class="container">
         <div class="row">
            <nav class="col-md-9" role="navigation">
               <div class="row">
                  <dl class="col-md-4" role="menu">
                     <dt>Browse</dt>
                     <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                  </dl>
                  <!-- logged-in individual or institutional user -->
                  <!-- unknown user -->
                  <!--institutional user not logged in-->
                  <dl class="col-md-4" role="menu">
                     <dt>Services</dt>
                     <dd><a href="https://bestpractice.bmj.com/login">Log in</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/registration">Create an account</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting
                           started</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/"
                           target="_blank">About CME/CPD</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/benefits-features/" target="_blank">About us</a>
                     </dd>
                     <dd><a href="https://bestpractice.bmj.com/info/app/" target="_blank">Mobile app</a></dd>
                     <dd><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></dd>
                     <dd>
                        <a
                           href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                        </a>
                     </dd>
                  </dl>
                  <dl class="col-md-4" role="menu">
                     <dt>Legal</dt>
                     <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                     <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and
                           conditions</a></dd>
                     <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                     <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie
                           policy</a></dd>
                  </dl>
               </div>
               <!-- row -->
            </nav>
            <div class="col-md-3">
               <ul>
                  <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo"
                           title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                  <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo"
                           title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                  <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo"
                           title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                  <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img
                           alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a>
                  </li>
               </ul>
               <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
               <p class="issn"><small>ISSN 2515-9615</small></p>
            </div>
         </div>
         <!-- row -->
      </div>
      <!-- container -->
   </footer>
   <div class="container modal-registration-form" aria-hidden="true">
      <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel"
         aria-hidden="true">
         <div class="modal-dialog modal-lg" role="document">
            <div class="modal-content pb-3">
               <div class="modal-header">
                  <div class="row">
                     <div class="col-md-12">
                        <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                        </button>
                     </div>
                     <div class="col-md-12">
                        <p>Please complete all fields.</p>
                     </div>
                  </div>
               </div>
               <div class="modal-body">
                  <div class="row">
                     <div class="col-md-12">
                        <form id="feedbackForm"
                           action="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#"
                           novalidate="novalidate">
                           <div class="row">
                              <div class="col-md-6">
                                 <div class="form-group floating-label">
                                    <label for="feedbackName">Name</label>
                                    <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                 </div>
                              </div>
                              <div class="col-md-6">
                                 <div class="form-group floating-label">
                                    <label for="feedbackEmail">Email</label>
                                    <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email"
                                       value="">
                                 </div>
                              </div>
                           </div>
                           <div class="row">
                              <div class="col-md-12">
                                 <h2 id="feedbackPageTitle" class="h3">Page: Pulmonary embolism - Approach | BMJ Best
                                    Practice</h2>
                              </div>
                           </div>
                           <input id="feedbackPage" name="feedbackPage" type="hidden"
                              value="Pulmonary embolism - Approach | BMJ Best Practice">
                           <div class="row">
                              <div class="col-md-4">
                                 <p>I have some feedback on:</p>
                                 <fieldset class="form-group" role="radiogroup">
                                    <legend>Feedback on: </legend>
                                    <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn"
                                          value="This page" checked="checked">&nbsp;This page</label>
                                    <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn"
                                          value="This website">&nbsp;The website in general</label>
                                    <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn"
                                          value="Something else">&nbsp;Something else</label>
                                 </fieldset>
                              </div>
                              <div class="col-md-8">
                                 <div class="form-group floating-label textarea">
                                    <label for="feedbackContent">I have some feedback on:</label>
                                    <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                 </div>
                              </div>
                           </div>
                           <div class="row">
                              <div class="col-md-12">
                                 <p>We will respond to all feedback.</p>
                              </div>
                           </div>
                           <div class="row">
                              <div class="col-md-12">
                                 <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                 </button>
                              </div>
                           </div>
                           <div class="row smTxt">
                              <div class="col-md-12">
                                 <p>For any urgent enquiries please contact our customer services team who are ready to
                                    help with any problems.</p>
                              </div>
                           </div>
                           <div class="row smTxt">
                              <div class="col-md-3">
                                 <p><b>Phone:</b> +44 (0) 207 111 1105</p>
                              </div>
                              <div class="col-md-3">
                                 <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                              </div>
                           </div>
                        </form>
                     </div>
                  </div>
               </div>
            </div>
         </div>
      </div>
      <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog"
         aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
         <div class="modal-dialog modal-lg" role="document">
            <div class="modal-content pb-3">
               <div class="modal-body">
                  <div class="row">
                     <div class="col-md-12">
                        <h2>Thank you</h2>
                        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                        </button>
                     </div>
                  </div>
                  <div class="row">
                     <div class="col-md-12">
                        <p>Your feedback has been submitted successfully.</p>
                     </div>
                  </div>
               </div>
            </div>
         </div>
      </div>
      <div id="feedBackBtn">
         <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#"><span
                  class="material-icons"></span>&nbsp;FEEDBACK</a></p>
      </div>
   </div>
   <script type="text/javascript" src="../js/common.js"></script>
   <script type="text/javascript" src="../js/main.js"></script>        
      <script type="text/javascript" src="../js/comorbidities.js"></script>
   <script>
      // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
      /*<![CDATA[*/
      function dedupe(array) {
         var seen = {};
         return array.filter(function (item) {
            return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
         });
      }

      function TopicViewed(id, title, lang) {
         this.id = id;
         this.title = title;
         this.lang = lang;
      }
      jQuery(document).ready(function () {
         var topicId = 116;
         var topicLang = "en-gb";
         var topicTitle = "Pulmonary embolism";
         if (topicId) {

            var topicsViewed = [];
            if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
            }

            topicsViewed.unshift(new TopicViewed(topicId, topicTitle,
            topicLang)); // Add new topics at the beginning
            topicsViewed = dedupe(topicsViewed); // Remove duplicates
            if (topicsViewed.length > 15) { // Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0, 14);
            }

            localStorage.topicsViewed = JSON.stringify(topicsViewed);
         }
      });
      /*]]>*/
   </script>
   <!-- <script type="text/javascript">
         _linkedin_data_partner_id = "103646";
      </script> -->
   <script type="text/javascript">
      (function () {
         var s = document.getElementsByTagName("script")[0];
         var b = document.createElement("script");
         b.type = "text/javascript";
         b.async = true;
         b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js";
         s.parentNode.insertBefore(b, s);
      })();
   </script>
   <!-- <script type="text/javascript" data-cfasync="false">
         (function(W,i,s,e,P,o,p){W['WisePopsObject']=P;W[P]=W[P]||function()
         { (W[P].q=W[P].q||[]).push(arguments)}
         ,W[P].l=1*new Date();o=i.createElement(s),
         p=i.getElementsByTagName(s)[0];o.async=1;o.src=e;p.parentNode.insertBefore(o,p)
         })(window,document,'script','//loader.wisepops.com/get-loader.js?v=1&site=qudyiEfMBd','wisepops');
         window.WisePopsLoaderCallback = function(wisepops) {
                         wisepops._storage.visits = wisepops._storage.visits.slice(0, 2);
                         wisepops._storage._saveVisits();
                       };
      </script> -->
   <!-- <noscript>
         <img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=103646&fmt=gif" />
      </noscript> -->
   <!--[if lte IE 7]><script>var isIE7OrOlder = true; </script><![endif]-->
   <!--[if lte IE 9]><script type="text/javascript" src="/gzip_e7393341757851d76c3264b590cf5143/js/browserupdate.js" ></script>
      <![endif]-->
   <script src="../js/adsct" type="text/javascript"></script>
   <script type="text/javascript" id="createCookie">
      (function () {
         var b = "bestpractice.bmj.com\/topics\/en-gb\/116\/management-approach",
            a = function (a, b, d) {
               var e = "",
                  c = new Date;
               d && (c.setTime(c.getTime() + 864E5 * d), e = "; expires\x3d" + c.toGMTString());
               document.cookie = a + "\x3d" + b + e + "; path\x3d/; domain\x3dbmj.com"
            };
         a("RefTrack", b, 2);
         a("RefTrackGroup", "bestpractice.bmj.com", 2)
      })();
   </script>
   <script type="text/javascript" id="copyText">
      function getSelectionText() {
         var a = "";
         window.getSelection ? a = window.getSelection().toString() : document.selection && "Control" != document
            .selection.type && (a = document.selection.createRange().text);
         return a
      }
      document.addEventListener("copy", function (a) {
         dataLayer.push({
            event: "textCopied",
            clipboardText: getSelectionText(),
            clipboardLength: getSelectionText().length
         })
      });
   </script>
   <script type="text/javascript" id="facebookPixel">
      ! function (b, e, f, g, a, c, d) {
         b.fbq || (a = b.fbq = function () {
               a.callMethod ? a.callMethod.apply(a, arguments) : a.queue.push(arguments)
            }, b._fbq || (b._fbq = a), a.push = a, a.loaded = !0, a.version = "2.0", a.queue = [], c = e
            .createElement(f), c.async = !0, c.src = g, d = e.getElementsByTagName(f)[0], d.parentNode.insertBefore(
               c, d))
      }(window, document, "script", "https://connect.facebook.net/en_US/fbevents.js");
      fbq("init", "414393182248444");
      fbq("track", "PageView");
   </script>
   <noscript><img height="1" width="1" style="display:none"
         src="https://www.facebook.com/tr?id=414393182248444&amp;ev=PageView&amp;noscript=1"></noscript>
   <button id="scrollTop" class="material-scrolltop" type="button"><span class="material-icons"></span></button>
   <script src="../js/saved_resource" type="text/javascript"></script>
</body>

</html>